{
    "data": [
        {
            "id": "urn:summary_document_report:quartr.com:2936526:0",
            "title": "TDAY: Digital revenue hit a record 47%+ of total, with 2026 guidance for further digital-led growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 saw record digital revenue share and strong Adjusted EBITDA growth, with digital now 47%+ of total revenue. 2026 guidance calls for digital to exceed 50% of revenue and double-digit growth in cash flow and Adjusted EBITDA. </span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A2936526-e06f6c5edfd2351deff9364183743b81\" target=\"_blank\">USA TODAY Co., Inc. [TDAY] SEC 8-K Current Report — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2936526:0-tday-digital-revenue-hit-a-record-47-of-total-with-2026-guidance-for-further-digital-led-growth/",
            "pub_date": "2026-02-26 21:08:54",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ5769Ua:0",
            "title": "REG - Raymond James WM Augmentum Fintech - Form 8.3 - Augmentum Fintech PLC 260226",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 5769U  Raymond James Wealth Management Ltd  26 February 2026   </span><p class=\"\"><span>FORM 8.3</span></p><p class=\"\"><span>PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY</span></p><p class=\"\"><span>A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</span></p><p class=\"\"><span>Rule 8.3 of the Takeover Code (the \"Code\")</span></p><p class=\"\"><span>1.         KEY INFORMATION</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>(a) Full name of discloser:</span></p></td><td><p class=\"\"><span>Raymond James Investment Services Ltd on behalf of discretionary clients</span></p></td></tr><tr><td><p class=\"\"><span>(b) Owner or controller of interests and short positions disclosed, if different from 1(a):</span></p><p class=\"\"><span>     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.</span></p></td><td><p class=\"\"><span>Platform Securities (Nominees) Ltd.</span></p></td></tr><tr><td><p class=\"\"><span>(c) Name of offeror/offeree in relation to whose relevant securities this form relates:</span></p><p class=\"\"><span>     Use a separate form for each offeror/offeree</span></p></td><td><p class=\"\"><span>Augmentum Fintech PLC    </span></p></td></tr><tr><td><p class=\"\"><span>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:</span></p></td><td><p class=\"\"><span>N/A</span></p></td></tr><tr><td><p class=\"\"><span>(e) Date position held/dealing undertaken:</span></p><p class=\"\"><span>     For an opening position disclosure, state the latest practicable date prior to the disclosure</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td></tr><tr><td><p class=\"\"><span>(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?</span></p><p class=\"\"><span>     If it is a cash offer or possible cash offer, state \"N/A\"</span></p></td><td><p class=\"\"><span>Frontier Bidco Limited</span></p></td></tr></tbody></table></div><p class=\"\"><span>2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE</span></p><p class=\"\"><span>If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.</span></p><p class=\"\"><span>(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class of relevant security:</span></p></td><td colspan=\"4\"><p class=\"\"><span>Ord 10p</span></p></td></tr><tr><td rowspan=\"2\"></td><td colspan=\"2\"><p class=\"\"><span>Interests</span></p></td><td colspan=\"2\"><p class=\"\"><span>Short positions</span></p></td></tr><tr><td><p class=\"\"><span>Number</span></p></td><td><p class=\"\"><span>%</span></p></td><td><p class=\"\"><span>Number</span></p></td><td><p class=\"\"><span>%</span></p></td></tr><tr><td><p class=\"\"><span>(1) Relevant securities owned and/or controlled:</span></p></td><td><p class=\"\"><span>2,475,023</span></p></td><td><p class=\"\"><span>1.48</span></p></td><td></td><td></td></tr><tr><td><p class=\"\"><span>(2) Cash-settled derivatives:</span></p></td><td></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>(3) Stock-settled derivatives (including options) and agreements to purchase/sell:</span></p></td><td></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>     TOTAL:</span></p></td><td><p class=\"\"><span>2,475,023</span></p></td><td><p class=\"\"><span>1.48</span></p></td><td></td><td></td></tr></tbody></table></div><p class=\"\"><span>All interests and all short positions should be disclosed.</span></p><p class=\"\"><span>Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).</span></p><p class=\"\"><span>(b)        Rights to subscribe for new securities (including directors' and other employee options)</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security in relation to which subscription right exists:</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details, including nature of the rights concerned and relevant percentages:</span></p></li></ul><p class=\"\"><span>3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE</span></p><p class=\"\"><span>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</span></p><p class=\"\"><span>The currency of all prices and other monetary amounts should be stated.</span></p><p class=\"\"><span>(a)        Purchases and sales</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Purchase/sale</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of securities</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Price per unit</span></p></li></ul><p class=\"\"><span>(b)        Cash-settled derivative transactions</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Product description</span></p><p class=\"\"><span>e.g. CFD</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nature of dealing</span></p><p class=\"\"><span>e.g. opening/closing a long/short position, increasing/reducing a long/short position</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of reference securities</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Price per unit</span></p></li></ul><p class=\"\"><span>(c)        Stock-settled derivative transactions (including options)</span></p><p class=\"\"><span>(i)         Writing, selling, purchasing or varying</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Product description e.g. call option</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Writing, purchasing, selling, varying etc.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of securities to which option relates</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Exercise price per unit</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Type</span></p><p class=\"\"><span>e.g. American, European etc.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Expiry date</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Option money paid/ received per unit</span></p></li></ul><p class=\"\"><span>(ii)        Exercise</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Product description</span></p><p class=\"\"><span>e.g. call option</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Exercising/ exercised against</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of securities</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Exercise price per unit</span></p></li></ul><p class=\"\"><span>(d)        Other dealings (including subscribing for new securities)</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nature of dealing</span></p><p class=\"\"><span>e.g. subscription, conversion</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Price per unit (if applicable)</span></p></li></ul><p class=\"\"><span>4.         OTHER INFORMATION</span></p><p class=\"\"><span>(a)        Indemnity and other dealing arrangements</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:</span></p><p class=\"\"><span>Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state \"none\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>None</span></p></li></ul><p class=\"\"><span>(b)        Agreements, arrangements or understandings relating to options or derivatives</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:</span></p><p class=\"\"><span>(i)  the voting rights of any relevant securities under any option; or</span></p><p class=\"\"><span>(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:</span></p><p class=\"\"><span>If there are no such agreements, arrangements or understandings, state \"none\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>None</span></p></li></ul><p class=\"\"><span>(c)        Attachments</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Is a Supplemental Form 8 (Open Positions) attached?</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>No</span></p></li></ul><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><span>Date of disclosure:</span></td><td><p class=\"\"><span>26/02/2026</span></p></td></tr><tr><td><span>Contact name:</span></td><td><p class=\"\"><span>                         Marco Abbatiello</span></p></td></tr><tr><td><span>Telephone number:</span></td><td><p class=\"\"><span>020 3798 3359</span></p></td></tr></tbody></table></div><p class=\"\"><span>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.</span></p><p class=\"\"><span>The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  RETXQLFLQLLBBBV</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ5769Ua:0-reg-raymond-james-wm-augmentum-fintech-form-8-3-augmentum-fintech-plc-260226/",
            "pub_date": "2026-02-26 21:09:02",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_slides:quartr.com:2936523:0",
            "title": "MRP: Q4 net income and AFFO were strong, with portfolio yield and capital deployment both rising",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 net income reached $122.2m and AFFO $125.6m, with full-year AFFO at $427.9m ($2.58/share). Invested capital outside Lennar MPA grew by $2.4bn, and the portfolio yield rose to 9.2%. Conservative leverage, strong liquidity, and robust dividend growth support a positive outlook.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Aslides%3Aquartr.com%3A2936523-e849e0483a8f43612ba3ba51e53d8a07\" target=\"_blank\">Millrose Properties, Inc. [MRP] Slides Release — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:2936523:0-mrp-q4-net-income-and-affo-were-strong-with-portfolio-yield-and-capital-deployment-both-rising/",
            "pub_date": "2026-02-26 21:09:05",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM0OW:0",
            "title": "TriMas Q4 sales rise 12.5%, boosts buyback",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Industrial products maker's Q4 net sales rose 12.5% yr/yr</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company repurchased over 3 mln shares, increased buyback authorization</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Aerospace segment moved to discontinued operations, divestiture on track for Q1 2026</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>TriMas expects 2026 sales growth of 3% to 6% year-over-year</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company anticipates over 300 basis points improvement in operating profit margin in 2026</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>TriMas plans to use Aerospace sale proceeds for growth investments and share repurchases</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>PACKAGING GROWTH - Q4 sales growth driven by higher demand in industrial and life science markets, offset by softer demand in food and beverage packaging</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>COST REDUCTION - TriMas implemented cost reduction initiatives expected to generate $15 million in annualized savings</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>AEROSPACE DIVESTITURE - Aerospace segment moved to discontinued operations; divestiture on track to close in Q1 2026</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Beat/Miss</span></p></td><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>Consensus Estimate</span></p></td></tr><tr><td><p class=\"\"><span>Q4 Sales</span></p></td><td><p class=\"\"><span>Beat</span></p></td><td><p class=\"\"><span>$256.50 mln</span></p></td><td><p class=\"\"><span>$143.11 mln (1 Analyst)</span></p></td></tr><tr><td><p class=\"\"><span>Q4 Adjusted EPS</span></p></td><td><p class=\"\"><span>Beat</span></p></td><td><p class=\"\"><span>$0.40</span></p></td><td><p class=\"\"><span>$0.002 (1 Analyst)</span></p></td></tr><tr><td><p class=\"\"><span>Q4 EPS</span></p></td><td></td><td><p class=\"\"><span>$2.03</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The average consensus recommendation for the non-paper containers &amp; packaging peer group is \"buy\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for TriMas Corp is $41.50, about 12.6% above its February 25 closing price of $36.85</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 14 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM0OW:0-trimas-q4-sales-rise-12-5-boosts-buyback/",
            "pub_date": "2026-02-26 21:09:06",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM1L8:0",
            "title": "One Polish rate setter wanted a 75-bp rate hike in Jan, voting records show",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>    Polish Monetary Policy Council (MPC) member Joanna Tyrowicz submitted a motion to increase interest rates by 0.75 percentage points in January, which was not supported by other members, according to voting results published by the central bank on Thursday.</span></p><p class=\"\"><span>The Monetary Policy Council kept interest rates unchanged last month, with the key rate remaining at 4.0%.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM1L8:0-one-polish-rate-setter-wanted-a-75-bp-rate-hike-in-jan-voting-records-show/",
            "pub_date": "2026-02-26 21:09:11",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_report:quartr.com:2936511:0",
            "title": "PNTG: Revenue surged 36% to $947.7M, with strong growth in home health, hospice, and senior living",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Revenue grew 36% to $947.7M, driven by acquisitions and organic growth, with net income up to $29.6M and adjusted EBITDA at $72.5M. Home health and hospice led segment growth, while senior living also expanded. Risks include reimbursement changes, labor costs, and regulatory scrutiny.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A2936511-a4b01127e413b638048d2bb08e973967\" target=\"_blank\">The Pennant Group, Inc. [PNTG] SEC 10-K Annual Report — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2936511:0-pntg-revenue-surged-36-to-947-7m-with-strong-growth-in-home-health-hospice-and-senior-living/",
            "pub_date": "2026-02-26 21:09:14",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZM175:0",
            "title": "Vistra beats fourth-quarter core profit estimates on AI-driven power demand",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>        Power producer Vistra Corp </span><span> beat Wall Street expectations for fourth-quarter adjusted core profit on Thursday, as an AI-driven surge in electricity demand from data centers fueled earnings.</span></p><p class=\"\"><span>U.S. power consumption is expected to rise sharply through this year and the next, driven by the rapid expansion of data centers for artificial intelligence services and cryptocurrency, and the switch to electric heating and transportation by households and businesses. </span></p><p class=\"\"><span>Big Tech companies are also trying to secure long-term electricity supply contracts to power AI-led services and data centers.</span></p><p class=\"\"><span>Earlier this year, Meta Platforms signed a 20-year agreement  to buy power from three of Vistra's nuclear plants in the U.S. heartland to build small modular reactors.</span></p><p class=\"\"><span>Vistra, in January, also announced a $4.7 billion agreement to acquire Cogentrix Energy and its 10 natural gas-fired plants from Quantum Capital Group to boost capacity for growing power needs.</span></p><p class=\"\"><span>The power producer in November forecast 2026 adjusted core profit higher than its outlook for 2025, signaling confidence in its growing power generation portfolio and strong demand across U.S. markets. </span></p><p class=\"\"><span>The company expects 2026 adjusted core profit between $6.8 billion and $7.6 billion, up from its 2025 forecast range of $5.7 billion to $5.9 billion, as it expands gas-fired and clean energy capacity.</span></p><p class=\"\"><span>However, Vistra's fourth‑quarter profit of $233 million narrowed from $490 million a year earlier.</span></p><p class=\"\"><span>The Irving, Texas-based company posted an adjusted core profit of $1.74 billion for the three months ended December 31, above analysts' average estimate of $1.68 billion, according to data compiled by LSEG.</span></p><p class=\"\"><span>Shares of the company rose 1.8% in premarket trading.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZM175:0-vistra-beats-fourth-quarter-core-profit-estimates-on-ai-driven-power-demand/",
            "pub_date": "2026-02-26 21:09:20",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ5771Ua:0",
            "title": "REG - Legal&Gen UCITS ETF - Net Asset Value(s)",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><span>RNS Number : 5771U  Legal &amp; General UCITS ETF PLC  26 February 2026   </span><p class=\"\"></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Funds</span></p></td><td><p class=\"\"><span>Date</span></p></td><td><p class=\"\"><span>ISIN code</span></p></td><td><p class=\"\"><span>Shares in Issue</span></p></td><td><p class=\"\"><span>Currency</span></p></td><td><p class=\"\"><span>Net Asset Value</span></p></td><td><p class=\"\"><span>NAV/per share Base</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Market Neutral Commodities UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE000IIHLZL0</span></p></td><td><p class=\"\"><span>3660000</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>37121881.57</span></p></td><td><p class=\"\"><span>10.143</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G FTSE 100 Leveraged (Daily 2x) UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00B4QNJJ23</span></p></td><td><p class=\"\"><span>31878</span></p></td><td><p class=\"\"><span>GBP</span></p></td><td><p class=\"\"><span>20957688.13</span></p></td><td><p class=\"\"><span>657.434</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G FTSE 100 Super Short Strategy (Daily 2x) UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00B4QNK008</span></p></td><td><p class=\"\"><span>6378543</span></p></td><td><p class=\"\"><span>GBP</span></p></td><td><p class=\"\"><span>12050285.92</span></p></td><td><p class=\"\"><span>1.889</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G DAX Daily 2x Long UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00B4QNHH68</span></p></td><td><p class=\"\"><span>63441</span></p></td><td><p class=\"\"><span>EUR</span></p></td><td><p class=\"\"><span>45978178.17</span></p></td><td><p class=\"\"><span>724.739</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G DAX Daily 2x Short UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00B4QNHZ41</span></p></td><td><p class=\"\"><span>37111236</span></p></td><td><p class=\"\"><span>EUR</span></p></td><td><p class=\"\"><span>21084442.39</span></p></td><td><p class=\"\"><span>0.568</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Longer Dated All Commodities UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00B4WPHX27</span></p></td><td><p class=\"\"><span>27464333</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>794650655.28</span></p></td><td><p class=\"\"><span>28.934</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Multi-Strategy Enhanced Commodities UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00BFXR6159</span></p></td><td><p class=\"\"><span>63551509</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>1033644230.81</span></p></td><td><p class=\"\"><span>16.265</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Multi-Strategy Enhanced Commodities USD Dist UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE000IYBMW97</span></p></td><td><p class=\"\"><span>4193036</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>45480209.54</span></p></td><td><p class=\"\"><span>10.847</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Multi-Strategy Enhanced Commodities GBP Hedge Acc UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00011CA799</span></p></td><td><p class=\"\"><span>66281217</span></p></td><td><p class=\"\"><span>GBP</span></p></td><td><p class=\"\"><span>787654629.80</span></p></td><td><p class=\"\"><span>11.884</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Multi-Strategy Enhanced Commodities GBP Hedge Dist UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE0004O92CM1</span></p></td><td><p class=\"\"><span>3682400</span></p></td><td><p class=\"\"><span>GBP</span></p></td><td><p class=\"\"><span>43147547.30</span></p></td><td><p class=\"\"><span>11.717</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G Multi-Strategy Enhanced Commodities ex-Agriculture &amp; Livestock USD ACC</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE000MQ5XEW1</span></p></td><td><p class=\"\"><span>5111400</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>68995662.77</span></p></td><td><p class=\"\"><span>13.498</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G New Energy Commodities UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE000BLN64M9</span></p></td><td><p class=\"\"><span>835006</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>11502351.32</span></p></td><td><p class=\"\"><span>13.775</span></p></td></tr><tr><td><p class=\"\"><span>L&amp;G All Commodities UCITS ETF</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td><td><p class=\"\"><span>IE00BF0BCP69</span></p></td><td><p class=\"\"><span>10150110</span></p></td><td><p class=\"\"><span>USD</span></p></td><td><p class=\"\"><span>180506942.22</span></p></td><td><p class=\"\"><span>17.784</span></p></td></tr></tbody></table></div><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  NAVGZGZZFVLGVZM</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ5771Ua:0-reg-legal-gen-ucits-etf-net-asset-value-s/",
            "pub_date": "2026-02-26 21:09:45",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM0OT:0",
            "title": "Delcath Q4 revenue rises 37%, beats estimates",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Interventional oncology firm's Q4 revenue rose, beating analyst expectations</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company reported Q4 net loss but achieved positive adjusted EBITDA</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company repurchased 628,572 shares for $6 mln under buyback program</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company expects 2026 revenue of at least $100 mln, driven by HEPZATO KIT volume growth</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Delcath anticipates gross margins between 84% and 87% for fiscal year 2026</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company aims for accelerated adoption through site activations and commercial expansion</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>HEPZATO GROWTH - 140% increase in HEPZATO procedure volume compared to 2024 drove revenue growth</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>CLINICAL TRIAL RESULTS - Positive results from CHOPIN trial and other studies increased awareness and demand</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>EXPANDED CAPACITY - 28 active centers contributed to increased procedure volume and revenue</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Beat/Miss</span></p></td><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>Consensus Estimate</span></p></td></tr><tr><td><p class=\"\"><span>Q4 Revenue</span></p></td><td><p class=\"\"><span>Beat</span></p></td><td><p class=\"\"><span>$20.73 mln</span></p></td><td><p class=\"\"><span>$20.33 mln (7 Analysts)</span></p></td></tr><tr><td><p class=\"\"><span>Q4 EPS</span></p></td><td></td><td><p class=\"\"><span>-$0.05</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Q4 Net Income</span></p></td><td></td><td><p class=\"\"><span>-$1.90 mln</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Q4 Gross Profit</span></p></td><td></td><td><p class=\"\"><span>$17.72 mln</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Q4 Operating Expenses</span></p></td><td></td><td><p class=\"\"><span>$19.90 mln</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Q4 Operating Income</span></p></td><td></td><td><p class=\"\"><span>-$2.18 mln</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Delcath Systems Inc is $22.00, about 115.5% above its February 25 closing price of $10.21</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 26 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM0OT:0-delcath-q4-revenue-rises-37-beats-estimates/",
            "pub_date": "2026-02-26 21:09:47",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L6N3ZM0QZ:0",
            "title": "Major Gulf markets ease as investors await US-Iran developments",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>By Amna Mariyam</span></p><p class=\"\"><span>    Major Gulf stock markets fell on Thursday as investors maintained a risk-averse approach amid heightened geopolitical tensions and uncertainty surrounding a third round of U.S.-Iran nuclear talks set to take place in Geneva later in the day.</span></p><p class=\"\"><span>Saudi Arabia's benchmark stock index </span><span> dropped 1.3%, marking its second consecutive week of decline. Losses were broad-based, led by energy stocks, with Saudi Aramco </span><span> dropping 3% — its steepest one-day decline in nine months — after the company confirmed damage at its Juaymah terminal and subsequent delivery cancellations.</span></p><p class=\"\"><span>Al Rajhi Bank </span><span>, the world's largest Islamic lender, fell 1.4%, and Saudi National Bank </span><span>, the country's largest lender by assets, dropped 1.7%.</span></p><p class=\"\"><span>Reuters reported that Saudi Arabia is ramping up oil production and exports as part of contingency measures to mitigate potential disruptions from a U.S. strike on Iran.</span></p><p class=\"\"><span>The robust non-oil economic sector could aid a market rebound if geopolitical tensions subside, according to George Pavel, general manager at Naga.com Middle East.</span></p><p class=\"\"><span>Dubai's main stock index </span><span> retreated 0.8%, weighed down by banking and real estate stocks. Emirates NBD Bank </span><span> plunged over 4%, marking its worst daily performance in more than three months, while Emaar Properties </span><span>, a leading real estate developer, fell 1.2%.</span></p><p class=\"\"><span>On Wednesday, the UAE's Central Bank unveiled plans to establish a sovereign financial cloud infrastructure in collaboration with G42 subsidiary Core42.</span></p><p class=\"\"><span>Abu Dhabi's index </span><span> edged 0.4% lower, extending a cautious trading pattern after two flat sessions. The market remained near historical highs as investors awaited clearer regional developments. Alpha Dhabi Holding </span><span> and Aldar Properties </span><span> both dropped 0.4%.</span></p><p class=\"\"><span>However, strong fourth-quarter corporate earnings in Abu Dhabi and a positive economic outlook could provide upward momentum once geopolitical risks subside, though oil price fluctuations remain a key concern, said Pavel.</span></p><p class=\"\"><span>Bloomberg News reported that Shell </span><span> is in talks with ADNOC and others regarding the sale of its stake in an Australian LNG project.</span></p><p class=\"\"><span>Qatar's stock index </span><span> tumbled 1.9%, marking its steepest single-day decline since mid-June, with all sectors closing in negative territory. Shares of Qatar National Bank </span><span>, the region's largest lender, dropped 3%, representing its biggest single-day loss in over five months. Qatar Aluminum Manufacturing Co </span><span> sank 3.5%, its largest one-day drop in nearly 11 months.</span></p><p class=\"\"><span>Outside the Gulf, Egypt's blue-chip index </span><span> gained 0.4%, seeking to recover from Wednesday's losses, as sentiment was bolstered by the IMF's completion of two reviews of Egypt's economic reform programme and a Resilience and Sustainability Facility (RSF) review, paving the way for disbursements of about $2.3 billion.</span></p><p class=\"\"><span>Commercial International Bank </span><span>, the country's leading private lender, advanced 1.1%, while Telecom Egypt </span><span> surged 3.4% after reporting a fourfold rise in its fourth-quarter profits.</span></p><p class=\"\"><span>The Kuwait Bourse (.BKP) was closed on account of National Day and Liberation Day.</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Saudi Arabia</span></p></td><td><p class=\"\"><span>            .TASI dropped 1.3% to 10,709</span></p></td></tr><tr><td><p class=\"\"><span>Abu Dhabi</span></p></td><td><p class=\"\"><span>            .FTFADGI eased 0.4% to 10,595</span></p></td></tr><tr><td><p class=\"\"><span>Dubai</span></p></td><td><p class=\"\"><span>            .DFMGI shed 0.8% to 6,625</span></p></td></tr><tr><td><p class=\"\"><span>Qatar</span></p></td><td><p class=\"\"><span>            .QSI dipped 1.9% to 11,055</span></p></td></tr><tr><td><p class=\"\"><span>Egypt</span></p></td><td><p class=\"\"><span>            .EGX30 added 0.4% to 49,213</span></p></td></tr><tr><td><p class=\"\"><span>Bahrain</span></p></td><td><p class=\"\"><span>            .BAX rose 0.1% to 2,061</span></p></td></tr><tr><td><p class=\"\"><span>Oman</span></p></td><td><p class=\"\"><span>            .MSX30 advanced 0.1% to 7,393</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L6N3ZM0QZ:0-major-gulf-markets-ease-as-investors-await-us-iran-developments/",
            "pub_date": "2026-02-26 21:10:05",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_report:quartr.com:2936522:0",
            "title": "GIL: Net sales rose 10.7% to $3.62B, with adjusted net earnings up 9.9% to $538M",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Net sales grew 10.7% to $3.62B, driven by the HanesBrands acquisition and strong Activewear performance. Adjusted net earnings rose 9.9% to $538M, while reported net earnings declined slightly due to higher restructuring and acquisition costs. The company paused share repurchases to prioritize deleveraging after the HanesBrands deal.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A2936522-4295e51fc5d18f2ce684d2c283fba48e\" target=\"_blank\">Gildan Activewear Inc. [GIL] SEC 40-F Annual Report — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2936522:0-gil-net-sales-rose-10-7-to-3-62b-with-adjusted-net-earnings-up-9-9-to-538m/",
            "pub_date": "2026-02-26 21:10:11",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_report:quartr.com:2936525:0",
            "title": "INSW: Strong 2025 results: $843M revenue, $309M net income, $145M dividends, robust liquidity, ongoing fleet renewal",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>2025 saw strong financial performance with $843M in shipping revenues and $309M net income, despite lower rates in Product Carriers. Liquidity rose to $724M, $145M was returned to shareholders, and the company continued fleet renewal and deleveraging. Geopolitical and regulatory risks remain significant.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A2936525-584a9864de07206ecd2715cec45f0c12\" target=\"_blank\">International Seaways, Inc. [INSW] SEC 10-K Annual Report — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2936525:0-insw-strong-2025-results-843m-revenue-309m-net-income-145m-dividends-robust-liquidity-ongoing-fleet-renewal/",
            "pub_date": "2026-02-26 21:10:18",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_report:quartr.com:2936527:0",
            "title": "MNKD: 2025 revenue up 22% to $349M, net income $5.9M, boosted by Afrezza, Tyvaso DPI, and Furoscix",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Total 2025 revenues rose 22% to $349M, driven by Afrezza growth, Tyvaso DPI royalties, and the addition of Furoscix post-scPharma acquisition. Net income was $5.9M, with higher R&amp;D and SG&amp;A expenses, and the company closed a $325M term loan to fund expansion.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A2936527-094b5a7624ec0e7be71c173335365bf2\" target=\"_blank\">MannKind Corporation [MNKD] SEC 10-K Annual Report — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2936527:0-mnkd-2025-revenue-up-22-to-349m-net-income-5-9m-boosted-by-afrezza-tyvaso-dpi-and-furoscix/",
            "pub_date": "2026-02-26 21:10:42",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_slides:quartr.com:2936484:0",
            "title": "ANIK: Commercial Channel growth and operational discipline offset OEM declines, supporting FY26 revenue outlook",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Commercial Channel and International OA Pain segments drove double-digit growth, offsetting OEM declines and pricing headwinds. FY25 revenue fell 6% to $112.8M, but cash flow and margins improved, with FY26 guidance projecting up to 9% revenue growth.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Aslides%3Aquartr.com%3A2936484-dbef4a5f676179413ba103a8f172ebe1\" target=\"_blank\">Anika Therapeutics Inc. [ANIK] Slides Release — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:2936484:0-anik-commercial-channel-growth-and-operational-discipline-offset-oem-declines-supporting-fy26-revenue-outlook/",
            "pub_date": "2026-02-26 21:04:15",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ5765Ua:0",
            "title": "REG - RBC Europe Ltd LondonMetric - Form 8.3 - LondonMetric Property plc",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 5765U  RBC Europe Limited  26 February 2026   </span><p class=\"\"><span>FORM 8.3</span></p><p class=\"\"><span>PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY</span></p><p class=\"\"><span>A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</span></p><p class=\"\"><span>Rule 8.3 of the Takeover Code (the \"Code\")</span></p><p class=\"\"><span>1.         KEY INFORMATION</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>(a) Full name of discloser:</span></p></td><td><p class=\"\"><span>RBC Europe Limited</span></p></td></tr><tr><td><p class=\"\"><span>(b) Owner or controller of interests and short positions disclosed, if different from 1(a):</span></p><p class=\"\"><span>     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.</span></p></td><td></td></tr><tr><td><p class=\"\"><span>(c) Name of offeror/offeree in relation to whose relevant securities this form relates:</span></p><p class=\"\"><span>     Use a separate form for each offeror/offeree</span></p></td><td><p class=\"\"><span>LondonMetric Property plc</span></p></td></tr><tr><td><p class=\"\"><span>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:</span></p></td><td></td></tr><tr><td><p class=\"\"><span>(e) Date position held/dealing undertaken:</span></p><p class=\"\"><span>     For an opening position disclosure, state the latest practicable date prior to the disclosure</span></p></td><td><p class=\"\"><span>25/02/2026</span></p></td></tr><tr><td><p class=\"\"><span>(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?</span></p><p class=\"\"><span>     If it is a cash offer or possible cash offer, state \"N/A\"</span></p></td><td><p class=\"\"><span>Picton Property Income Limited</span></p></td></tr></tbody></table></div><p class=\"\"><span>2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE</span></p><p class=\"\"><span>If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.</span></p><p class=\"\"><span>(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class of relevant security:</span></p></td><td colspan=\"4\"><p class=\"\"><span>ORD GBP0.01</span></p></td></tr><tr><td rowspan=\"2\"></td><td colspan=\"2\"><p class=\"\"><span>Interests</span></p></td><td colspan=\"2\"><p class=\"\"><span>Short positions</span></p></td></tr><tr><td><p class=\"\"><span>Number</span></p></td><td><p class=\"\"><span>%</span></p></td><td><p class=\"\"><span>Number</span></p></td><td><p class=\"\"><span>%</span></p></td></tr><tr><td><p class=\"\"><span>(1) Relevant securities owned and/or controlled:</span></p></td><td><p class=\"\"><span>11,209,462</span></p></td><td><p class=\"\"><span>0.47</span></p></td><td></td><td></td></tr><tr><td><p class=\"\"><span>(2) Cash-settled derivatives:</span></p></td><td></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>(3) Stock-settled derivatives (including options) and agreements to purchase/sell:</span></p></td><td></td><td></td><td></td><td></td></tr><tr><td><p class=\"\"><span>     TOTAL:</span></p></td><td><p class=\"\"><span>11,209,462</span></p></td><td><p class=\"\"><span>0.47</span></p></td><td></td><td></td></tr></tbody></table></div><p class=\"\"><span>All interests and all short positions should be disclosed.</span></p><p class=\"\"><span>Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).</span></p><p class=\"\"><span>(b)        Rights to subscribe for new securities (including directors' and other employee options)</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security in relation to which subscription right exists:</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details, including nature of the rights concerned and relevant percentages:</span></p></li></ul><p class=\"\"><span>3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE</span></p><p class=\"\"><span>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</span></p><p class=\"\"><span>The currency of all prices and other monetary amounts should be stated.</span></p><p class=\"\"><span>(a)        Purchases and sales</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class of relevant security</span></p></td><td><p class=\"\"><span>ORD GBP0.10</span></p></td></tr><tr><td><p class=\"\"><span>Purchase/sale</span></p></td><td><p class=\"\"><span>Purchase</span></p></td></tr><tr><td><p class=\"\"><span>Number of securities</span></p></td><td><p class=\"\"><span>1600</span></p></td></tr><tr><td><p class=\"\"><span>Price per unit</span></p></td><td><p class=\"\"><span>211.02p</span></p></td></tr></tbody></table></div><p class=\"\"><span>(b)        Cash-settled derivative transactions</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Product description</span></p><p class=\"\"><span>e.g. CFD</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nature of dealing</span></p><p class=\"\"><span>e.g. opening/closing a long/short position, increasing/reducing a long/short position</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of reference securities</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Price per unit</span></p></li></ul><p class=\"\"><span>(c)        Stock-settled derivative transactions (including options)</span></p><p class=\"\"><span>(i)         Writing, selling, purchasing or varying</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Product description e.g. call option</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Writing, purchasing, selling, varying etc.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of securities to which option relates</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Exercise price per unit</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Type</span></p><p class=\"\"><span>e.g. American, European etc.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Expiry date</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Option money paid/ received per unit</span></p></li></ul><p class=\"\"><span>(ii)        Exercise</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Product description</span></p><p class=\"\"><span>e.g. call option</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Exercising/ exercised against</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Number of securities</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Exercise price per unit</span></p></li></ul><p class=\"\"><span>(d)        Other dealings (including subscribing for new securities)</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Class of relevant security</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Nature of dealing</span></p><p class=\"\"><span>e.g. subscription, conversion</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Price per unit (if applicable)</span></p></li></ul><p class=\"\"><span>4.         OTHER INFORMATION</span></p><p class=\"\"><span>(a)        Indemnity and other dealing arrangements</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:</span></p><p class=\"\"><span>Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state \"none\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>NONE</span></p></li></ul><p class=\"\"><span>(b)        Agreements, arrangements or understandings relating to options or derivatives</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:</span></p><p class=\"\"><span>(i)  the voting rights of any relevant securities under any option; or</span></p><p class=\"\"><span>(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:</span></p><p class=\"\"><span>If there are no such agreements, arrangements or understandings, state \"none\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>NONE</span></p></li></ul><p class=\"\"><span>(c)        Attachments</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Is a Supplemental Form 8 (Open Positions) attached?</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>NO</span></p></li></ul><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Date of disclosure:</span></p></td><td><p class=\"\"><span>26/02/2026</span></p></td></tr><tr><td><p class=\"\"><span>Contact name:</span></p></td><td><p class=\"\"><span>Cameron Kentebe</span></p></td></tr><tr><td><p class=\"\"><span>Telephone number:</span></p></td><td><p class=\"\"><span>0191 279 7609 / 0191 230 7236</span></p></td></tr></tbody></table></div><p class=\"\"><span>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.</span></p><p class=\"\"><span>The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.</span></p><p class=\"\"><span>​</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  RETTFMJTMTMTBJF</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ5765Ua:0-reg-rbc-europe-ltd-londonmetric-form-8-3-londonmetric-property-plc/",
            "pub_date": "2026-02-26 21:04:17",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM19I:0",
            "title": "NTT Data And Ericsson Team Up To Scale Private 5G And Physical Ai For Enterprises",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Telefonaktiebolaget LM Ericsson </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>NTT DATA AND ERICSSON TEAM UP TO SCALE PRIVATE 5G AND PHYSICAL AI FOR ENTERPRISES</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM19I:0-ntt-data-and-ericsson-team-up-to-scale-private-5g-and-physical-ai-for-enterprises/",
            "pub_date": "2026-02-26 21:04:21",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM19L:0",
            "title": "STL Networks Gets Tax Demand Order For 60.6 Million Rupees",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>STL Networks Ltd </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>GETS TAX DEMAND ORDER FOR 60.6 MILLION RUPEES</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM19L:0-stl-networks-gets-tax-demand-order-for-60-6-million-rupees/",
            "pub_date": "2026-02-26 21:04:37",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_RSZ5767Ua:0",
            "title": "REG - AVI Japan Opport.Tst - Net Asset Value(s)",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 5767U  AVI Japan Opportunity Trust PLC  26 February 2026   </span><p class=\"\"></p><p class=\"\"><span>AVI JAPAN OPPORTUNITY TRUST PLC</span></p><p class=\"\"><span>It is announced that the un‑audited Net Asset Value per Ordinary share (inclusive of accumulated income) of AVI Japan Opportunity Trust plc, an investment trust managed by Asset Value Investors Limited, at the close of business on 25 February 2026 was as follows:</span></p><p class=\"\"><span>Net Asset Value:         187.98 pence</span></p><p class=\"\"><span>Legal Entity Identifier 894500IJ5QQD7FPT3J73</span></p><p class=\"\"><span>26 February 2026</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  NAVPPUCUPUPQGWQ</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_RSZ5767Ua:0-reg-avi-japan-opport-tst-net-asset-value-s/",
            "pub_date": "2026-02-26 21:04:47",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM0OP:0",
            "title": "Sempra beats Q4 adjusted EPS estimates, affirms FY profit view",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Energy infrastructure firm's Q4 revenue missed analyst expectations</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Adjusted EPS for Q4 beat analyst expectations</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company's adjusted net income for Q4 exceeded analyst estimates</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Sempra plans $65 bln capital expenditure from 2026 to 2030</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company targets 11% rate base CAGR and 95% regulated earnings mix</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Sempra affirms 2026 EPS guidance range of $4.80 to $5.30</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>CAPITAL INVESTMENTS - Sempra invested approximately $13 bln in 2025 to modernize energy infrastructure, focusing on Texas and California utilities</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>SIMPLIFICATION AND CAPITAL EFFICIENCY - Co took steps to simplify its business and improve capital efficiency, supporting future earnings growth</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>LNG STRATEGIC TRANSACTION - Sempra entered a strategic transaction to sell a 45% equity stake in Sempra Infrastructure Partners for $10 bln</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Beat/Miss</span></p></td><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>Consensus Estimate</span></p></td></tr><tr><td><p class=\"\"><span>Q4 Revenue</span></p></td><td><p class=\"\"><span>Miss</span></p></td><td><p class=\"\"><span>$3.75 bln</span></p></td><td><p class=\"\"><span>$4.05 bln (8 Analysts)</span></p></td></tr><tr><td><p class=\"\"><span>Q4 Adjusted EPS</span></p></td><td><p class=\"\"><span>Beat</span></p></td><td><p class=\"\"><span>$1.28</span></p></td><td><p class=\"\"><span>$1.17 (12 Analysts)</span></p></td></tr><tr><td><p class=\"\"><span>Q4 EPS</span></p></td><td></td><td><p class=\"\"><span>$0.54</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Q4 Adjusted Net Income</span></p></td><td><p class=\"\"><span>Beat</span></p></td><td><p class=\"\"><span>$841 mln</span></p></td><td><p class=\"\"><span>$780.92 mln (5 Analysts)</span></p></td></tr><tr><td><p class=\"\"><span>Q4 Net Income</span></p></td><td></td><td><p class=\"\"><span>$352 mln</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The average consensus recommendation for the multiline utilities peer group is \"buy\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Sempra is $101.00, about 6.9% above its February 25 closing price of $94.50</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM0OP:0-sempra-beats-q4-adjusted-eps-estimates-affirms-fy-profit-view/",
            "pub_date": "2026-02-26 21:04:51",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226009231:0",
            "title": "Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Plans to License or Monetize our Migraine and Inhalation Assets Continue</span></p><p class=\"\"><span>FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ — Pulmatrix, Inc. (\"Pulmatrix\" or the \"Company\") </span><span>, a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE(TM) technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</span></p><p class=\"\"><span>Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, \"Our focus in the fourth quarter was to advance steps to complete the proposed merger with Cullgen, a privately held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies for the treatment of pain, cancer and other diseases. We continue to work with Cullgen for approval from the China Securities Regulatory Commission, or CSRC, one of the closing conditions of the Merger. Pulmatrix and Cullgen agreed to waive the \"No Solicitation\" clause in the Merger Agreement to permit each party to explore transactions that may benefit our respective companies while still seeking approval from the CSRC. In conjunction with the proposed merger, Pulmatrix is currently in a process to license or partner its patent portfolio encompassing our iSPERSE(TM) technology, as well as three related clinical programs, including our Phase 2 ready acute migraine program.</span></p><p class=\"\"><span>Proposed Merger with Cullgen</span></p><p class=\"\"><span>As previously reported, on November 13, 2024, the Company entered into an agreement and plan of merger with Cullgen Inc. (\"Cullgen\"), as amended by Amendment No. 1 thereto on April 7, 2025 (the \"Merger Agreement\" and such transaction, the \"Merger\"). If the proposed Merger is completed, the business of Cullgen will continue as the business of the combined company.</span></p><p class=\"\"><span>Additional information about the Merger Agreement and proposed Merger was previously disclosed in a registration statement on Form S-4 (File No. 333-284993) initially filed with the Securities and Exchange Commission (the \"SEC\") on February 14, 2025, as amended on April 17, 2025, and May 7, 2025, and declared effective on May 9, 2025.</span></p><p class=\"\"><span>On June 16, 2025, the Company held a special meeting in lieu of the 2025 annual meeting of Pulmatrix stockholders, at which the Company's stockholders approved the Merger and related proposals. The closing of the Merger is subject to other customary closing conditions, including Nasdaq's approval of the listing of the shares of Pulmatrix common stock to be issued in connection with the Merger and approval from the CSRC.</span></p><p class=\"\"><span>On December 17, 2025, the Company and Cullgen mutually agreed to waive the \"No Solicitation\" clause in the Merger Agreement in order to permit each party to explore alternate transactions while continuing to work toward merger approval from the CSRC.</span></p><p class=\"\"><span>Pulmatrix Currently Seeking License or Monetization of Clinical Assets and Proprietary iSPERSE(TM) Technology</span></p><p class=\"\"><span>iSPERSE(TM) Technology</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>iSPERSE(TM), also licensed to MannKind Corporation and Cipla Technologies   for certain fields of use, utilizes particles that are engineered with a   small, dense and dispersible profile to exceed the performance of   traditional dry powder particles as the iSPERSE(TM) particles have the   dispersibility advantages of porous engineered particles. Pulmatrix   believes this results in superior drug delivery compared to traditional   oral and injectable forms of treatment for certain diseases.   </span></li><li class=\"listItem-bmN0_SHH\"><span>As of December 31, 2025, Pulmatrix's patent portfolio related to   iSPERSE(TM) included approximately 149 granted patents, 18 of which are   U.S.-granted patents, plus approximately 48 pending patent applications   in the U.S. and other jurisdictions. </span></li></ul><p class=\"\"><span>PUR3100</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>PUR3100, a Phase 2-ready asset, is an orally inhaled dihydroergotamine   (\"DHE\") engineered with Pulmatrix's iSPERSE(TM) dry powder inhalation   technology for the treatment of acute migraine has a Food and Drug   Administration acceptance of an Investigational New Drug (\"IND\")   application for PUR3100 and receipt of a \"study may proceed\" letter to   proceed with a Phase 2 study. The IND includes a Phase 2 clinical   protocol where safety and preliminary efficacy of PUR3100 will be   investigated in patients with acute migraine.   </span></li><li class=\"listItem-bmN0_SHH\"><span>The Phase 2 IND builds on the Phase 1 trial results of PUR3100, which   were published in 2024 in the peer-reviewed publication, Headache: The   Journal of Head and Face Pain. The study showed that PUR3100 achieved   peak exposures in the targeted therapeutic range and time to maximum   concentration occurred at five minutes after dosing at all dosing levels.   The PUR3100 dose groups also showed a lower incidence of nausea and no   vomiting compared to observations of nausea and vomiting in the   intravenously (\"IV\") administered DHE dose group. </span></li></ul><p class=\"\"><span>PUR1800</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>PUR1800 is a Narrow Spectrum Kinase Inhibitor (\"NSKI\"), engineered with   our iSPERSE(TM) technology, for the treatment of acute exacerbations in   chronic obstructive pulmonary disease (\"AECOPD\"). In 2023, Pulmatrix   presented complete results from a Phase 1b study of PUR1800 for AECOPD,   indicating PUR1800 was well-tolerated with no observed safety signals.   The topline data, along with the results from chronic toxicology studies,   support the continued development of PUR1800 for the treatment of AECOPD   and other inflammatory respiratory diseases.   </span></li><li class=\"listItem-bmN0_SHH\"><span>In 2024, Pulmatrix published an abstract titled \"Ex vivo evaluation of   the potential for Narrow Spectrum Kinase inhibitors as a treatment for   Idiopathic Pulmonary Fibrosis\". </span></li></ul><p class=\"\"><span>PUR1900</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>PUR1900, approved to proceed to a Phase 3 in India conducted by our   partner Cipla, is the Company's inhaled iSPERSE(TM) formulation of the   antifungal drug itraconazole being investigated for various indications.   The Company and its partner, Cipla, wound down a Phase 2b trial that the   Company was operating in 2024. Cipla has continued clinical development   outside the United States, and in 2025 completed their Phase 2 study in   India and have been approved by India's Central Drug Standard Control   Organization to proceed with a Phase 3 clinical trial.   </span></li><li class=\"listItem-bmN0_SHH\"><span>Pulmatrix will receive 2% royalties on any potential future net sales by   Cipla outside the United States should Cipla successfully market PUR1900   outside the United States. Within the United States, the Company and   Cipla share the rights 50/50 and will seek to monetize PUR1900 for   indications where an orally inhaled antifungal may provide a therapeutic   benefit or fulfill an unmet medical need. </span></li></ul><p class=\"\"><span>Fourth Quarter and Year-End 2025 Financial Results</span></p><p class=\"\"><span>Revenues decreased to nil for the year ended December 31, 2025, compared to $7.8 million for the year ended December 31, 2024. Revenues recognized for the year ended December 31, 2024, were primarily generated from the Cipla Agreement as related to our PUR1900 program, for which wind down activities were completed during the year ended December 31, 2024.</span></p><p class=\"\"><span>Research and development expenses decreased approximately $7.1 million to less than $0.1 million for the year ended December 31, 2025, compared to $7.2 million for the year ended December 31, 2024. The decrease was primarily due to the wind down of the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.</span></p><p class=\"\"><span>General and administrative expenses decreased approximately $2.7 million to $5.1 million for the year ended December 31, 2025, compared to $7.8 million for the year ended December 31, 2024. The decrease was primarily due to decreased employment and other operating costs due to the previously mentioned wind down, partially offset by incurred costs related to the proposed Merger.</span></p><p class=\"\"><span>The Company's total cash and cash equivalents balance as of December 31, 2025, was $4.1 million, compared to 9.5 million for the year ended December 31, 2024. The Company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund its operations into the first quarter of 2027.</span></p><pre class=\"preformatted-zagxxLT_\" data-no-swipe=\"true\"><span> </span><br/><span>                            PULMATRIX, INC. </span><br/><span>                      Consolidated Balance Sheets </span><br/><span>            (in thousands, except share and per share data) </span><br/><span> </span><br/><span>                                         December 31,    December 31, </span><br/><span>                                             2025            2024 </span><br/><span>                                        --------------  -------------- </span><br/><span>Assets </span><br/><span>Current assets: </span><br/><span>Cash and cash equivalents                $       4,088   $       9,521 </span><br/><span>Prepaid expenses and other current </span><br/><span> assets                                             41             399 </span><br/><span>                                            ----------      ---------- </span><br/><span>Total current assets                             4,129           9,920 </span><br/><span>Long-term restricted cash                           10              10 </span><br/><span>Other long-term assets                               -              13 </span><br/><span>                                            ----------      ---------- </span><br/><span>Total assets                             $       4,139   $       9,943 </span><br/><span>                                            ==========      ========== </span><br/><span>Liabilities and stockholders' equity </span><br/><span>Current liabilities: </span><br/><span>Accounts payable                         $         272   $         809 </span><br/><span>Accrued expenses and other current </span><br/><span> liabilities                                        57             120 </span><br/><span>                                            ----------      ---------- </span><br/><span>Total current liabilities                          329             929 </span><br/><span>Warrant liability                                    -              67 </span><br/><span>                                            ----------      ---------- </span></pre></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226009231:0/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_slides:quartr.com:2936492:0",
            "title": "FCN: Q4 2025 delivered double-digit revenue growth and margin expansion, led by Corporate Finance",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 saw 10.7% revenue growth and 9.7% net income growth year-over-year, with strong performance in Corporate Finance and Strategic Communications. Full-year Adjusted EBITDA rose 14.8%, while free cash flow and cash balances declined. </span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Aslides%3Aquartr.com%3A2936492-fecef9689ee8bbcdd5673d4c8ca3b708\" target=\"_blank\">FTI Consulting, Inc. [FCN] Slides Release — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:2936492:0-fcn-q4-2025-delivered-double-digit-revenue-growth-and-margin-expansion-led-by-corporate-finance/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226009222:0",
            "title": "Charles River Associates (CRA) Reports Fourth-Quarter and Full-Year 2025 Financial Results",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(13:05 GMT) </span></strong><span>*CRA Intl 4Q EPS $1.99 &gt;CRAI</span><br/><strong class=\"root-Tkn6WL2y\"><span>(13:05 GMT) </span></strong><span>*CRA Intl 4Q Adj EPS $2.06 &gt;CRAI</span><br/><strong class=\"root-Tkn6WL2y\"><span>(13:05 GMT) </span></strong><span>*CRA Intl 4Q Net $13.2M &gt;CRAI</span><br/><strong class=\"root-Tkn6WL2y\"><span>(13:05 GMT) </span></strong><span>*CRA Intl 4Q Rev $197M &gt;CRAI</span><br/><strong class=\"root-Tkn6WL2y\"><span>(13:05 GMT) </span></strong><span>Press Release: Charles River Associates (CRA) Reports Fourth-Quarter and Full-Year 2025 Financial Results</span></p><p class=\"\"><span>Fourth Quarter Revenue Increases 11.6% Year Over Year</span></p><p class=\"\"><span>Broad-based Contributions Drive Record Revenue and Profitability in Fiscal 2025</span></p><p class=\"\"><span>Board Expands Share Repurchase Authorization by $55 Million</span></p><p class=\"\"><span>BOSTON--(BUSINESS WIRE)--February 26, 2026--</span></p><p class=\"\"><span>Charles River Associates </span><span>, a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fourth quarter and fiscal year ended January 3, 2026.</span></p><p class=\"\"><span>\"For the eighth consecutive year, CRA established a new record for annual revenue,\" said Paul Maleh, CRA's President and Chief Executive Officer. \"Strong top-line growth drove record profitability as net income, earnings per diluted share, and EBITDA each set a new annual high. For the fourth quarter, we continued to see strength across our portfolio of services as total revenue increased 11.6% year over year to $197.0 million. Four practices--Antitrust &amp; Competition Economics, Energy, Forensic Services, and Labor &amp; Employment--led the way, with each generating double-digit revenue growth, while our Life Sciences and Risk, Investigations &amp; Analytics practices also expanded revenue year over year. Geographically, our North American and international operations both supported the quarter's revenue expansion, increasing 9.4% and 21.9%, respectively.\"</span></p><p class=\"\"><span>Highlights for Fourth Quarter Fiscal 2025</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Revenue grew 11.6% year over year to $197.0 million.   </span></li><li class=\"listItem-bmN0_SHH\"><span>Utilization was 78% and quarter-end headcount increased 1.4% year over   year.   </span></li><li class=\"listItem-bmN0_SHH\"><span>Net income decreased 12.0% year over year to $13.2 million, or 6.7% of   revenue, compared with $15.0 million, or 8.5% of revenue, in the fourth   quarter of fiscal 2024; non-GAAP net income decreased 2.1% year over year   to $13.7 million, or 7.0% of revenue, compared with $14.0 million, or   7.9% of revenue, in the fourth quarter of fiscal 2024.   </span></li><li class=\"listItem-bmN0_SHH\"><span>Earnings per diluted share decreased 8.7% year over year to $1.99 from   $2.18 in the fourth quarter of fiscal 2024; non-GAAP earnings per diluted   share increased 1.5% year over year to $2.06 from $2.03 in the fourth   quarter of fiscal 2024.   </span></li><li class=\"listItem-bmN0_SHH\"><span>Non-GAAP EBITDA remained relatively unchanged at $24.4 million, or   12.4% of revenue, compared with 13.9% of revenue in the fourth quarter of   fiscal 2024.   </span></li><li class=\"listItem-bmN0_SHH\"><span>On a constant currency basis relative to the fourth quarter of fiscal   2024, revenue, GAAP net income, and earnings per diluted share would have   been lower by $1.4 million, $0.2 million, and $0.04 per diluted share,   respectively. Non-GAAP net income, non-GAAP earnings per diluted share,   and non-GAAP EBITDA, would have been lower, by $0.2 million, $0.03 per   diluted share, and $0.4 million, respectively.   </span></li><li class=\"listItem-bmN0_SHH\"><span>CRA returned $3.7 million of capital to its shareholders via dividend   payments. </span></li></ul><p class=\"\"><span>Highlights for Full-Year Fiscal 2025</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Revenue grew 9.3% year over year to $751.6 million while company-wide   utilization was 77%.   </span></li><li class=\"listItem-bmN0_SHH\"><span>GAAP net income increased 17.4% year over year to $54.8 million, or   7.3% of revenue, or $8.14 per diluted share, compared with $46.7 million,   or 6.8% of revenue, or $6.74 per diluted share for the full year fiscal   2024. Non-GAAP net income increased 5.2% year over year to $55.3 million,   or 7.4% of revenue, or $8.23 per diluted share, compared with $52.6   million, or 7.7% of revenue, or $7.60 per diluted share for the full year   fiscal 2024.   </span></li><li class=\"listItem-bmN0_SHH\"><span>Non-GAAP EBITDA grew 7.1% to $96.8 million, or 12.9% of revenue,   compared with $90.4 million, or 13.2% of revenue, in fiscal 2024.   </span></li><li class=\"listItem-bmN0_SHH\"><span>On a constant currency basis relative to fiscal 2024, revenue, GAAP net   income, and earnings per diluted share would have been lower by $3.9   million, $0.7 million, and $0.10 per diluted share, respectively.   Non-GAAP net income, non-GAAP earnings per diluted share, and non-GAAP   EBITDA would have been lower by $0.7 million, $0.11 per diluted share,   and $0.9 million, respectively.   </span></li><li class=\"listItem-bmN0_SHH\"><span>For fiscal 2025, CRA returned $60.9 million of capital to its   shareholders, consisting of $13.8 million in dividend payments and $47.1   million in share repurchases of approximately 252,000 shares. </span></li></ul><p class=\"\"><span>Management Commentary and Financial Guidance</span></p><p class=\"\"><span>\"Our fiscal 2025 financial performance reflects our continued strength in the marketplace, and we are looking to continue our broad-based profitable growth in the years ahead,\" said Maleh. \"For full-year fiscal 2026, on a constant-currency basis relative to fiscal 2025, we expect revenue in the range of $785 million to $805 million, and non-GAAP EBITDA margin in the range of 12.0% to 13.0%.\"</span></p><p class=\"\"><span>\"Based on current forecasts, we expect that currency effects will decrease our reported revenue by roughly $5 million and will decrease our reported EBITDA by less than $1 million when stated on a constant currency basis. In addition, non-cash forgivable loan amortization, which is reflected as an expense when presenting EBITDA metrics, is expected to increase approximately $15 million, or more than 30% year over year, in fiscal 2026 due to the increase in talent investments completed in fiscal 2025. Finally, as a reminder, fiscal 2026 returns to CRA's typical 52-week year, whereas fiscal 2025 contained an extra week and resulted in a 53-week year. While we are pleased with CRA's strong performance in 2025, we remain mindful that uncertain global macroeconomic, business, and political conditions can affect our business.\"</span></p><p class=\"\"><span>CRA does not provide reconciliations of its annual non-GAAP EBITDA margin guidance to GAAP net income margin because the Company is unable to estimate with reasonable certainty unusual gains or charges, foreign currency exchange rates, and the resulting effect of these items, and of equity awards, on CRA's taxes without unreasonable effort. These items are uncertain, depend on various factors, and may have a material effect on CRA's results computed in accordance with GAAP. A reconciliation between the historical GAAP and non-GAAP financial measures presented in this press release is provided in the financial tables at the end of this press release.</span></p><p class=\"\"><span>Share Repurchase Expansion and Quarterly Dividend</span></p><p class=\"\"><span>On February 26, 2026, CRA's Board of Directors authorized a $55.0 million expansion of the Company's existing share repurchase program, in addition to the $10.9 million currently remaining under the program. CRA may repurchase shares of its common stock in the open market or in privately negotiated transactions in accordance with applicable insider trading and other securities laws and regulations. The timing, amount and extent to which CRA repurchases shares will depend upon market conditions and other factors it may consider in its sole discretion.</span></p><p class=\"\"><span>The Board of Directors also authorized a quarterly cash dividend of $0.57 per common share, payable on March 20, 2026 to shareholders of record as of March 10, 2026. CRA expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain subject to the discretion of CRA's Board of Directors.</span></p><p class=\"\"><span>Conference Call Information and Prepared CFO Remarks</span></p><p class=\"\"><span>CRA will host a conference call today at 10:00 a.m. ET to discuss its fourth-quarter and fiscal-year 2025 financial results. To listen to the live call, please visit the \"Investor Relations\" section of CRA's website at http://www.crai.com, or dial (877) 709-8155 or (201) 689-8881. An archived version of the webcast will be available on CRA's website for one year.</span></p><p class=\"\"><span>In combination with this press release, CRA has posted prepared remarks by its CFO Eric Nierenberg under \"Quarterly Earnings\" in the \"Investor Relations\" section on CRA's website at http://www.crai.com. These remarks are offered to provide the investment community with additional background on CRA's financial results prior to the start of the conference call.</span></p><p class=\"\"><span>About Charles River Associates (CRA)</span></p><p class=\"\"><span>Charles River Associates(R) is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.</span></p><p class=\"\"><span>NON-GAAP FINANCIAL MEASURES</span></p><p class=\"\"><span>In this press release, CRA has supplemented the presentation of its financial results calculated in accordance with U.S. generally accepted accounting principles or \"GAAP\" with the following financial measures that are not calculated in accordance with GAAP: non--GAAP net income, non--GAAP earnings per diluted share, non--GAAP EBITDA and non-GAAP EBITDA margin. CRA believes that the non-GAAP financial measures described in this press release are important to management and investors because these measures supplement the understanding of CRA's ongoing operating results and financial condition. In addition, these non-GAAP measures are used by CRA in its budgeting process, and the non-GAAP adjustments are made to the performance measures for some of CRA's performance-based compensation.</span></p><p class=\"\"><span>As used herein, CRA defines non-GAAP EBITDA as net income before interest expense (net), provision for income taxes, and depreciation and amortization further adjusted for the impact of certain items that we do not consider indicative of our core operating performance, such as non-cash amounts relating to valuation changes in contingent consideration, acquisition-related costs, foreign currency (gains) losses, net, restructuring costs and related tax effects. Non-GAAP net income and non-GAAP earnings per diluted share also exclude non-cash amounts relating to valuation changes in contingent consideration, acquisition-related costs, foreign currency (gains) losses, net, restructuring costs and related tax effects. This press release also presents certain current fiscal period financial measures on a \"constant currency\" basis in order to isolate the effect that foreign currency exchange rate fluctuations can have on CRA's financial results. These constant currency measures are determined by recalculating the current fiscal period local currency financial measure using the specified corresponding prior fiscal period's foreign exchange rates.</span></p><p class=\"\"><span>All of the non-GAAP financial measures referred to above should be considered in conjunction with, and not as a substitute for, the GAAP financial information presented in this press release. The financial measures identified in this press release as \"non-GAAP\" are reconciled to their GAAP comparable measures in the financial tables appended to the end of this press release. In evaluating these non-GAAP financial measures, note that the non-GAAP financial measures used by CRA may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.</span></p><p class=\"\"><span>SAFE HARBOR STATEMENT</span></p><p class=\"\"><span>Statements in this press release concerning our future business, operating results and financial condition, including those concerning guidance on future revenue and non-GAAP EBITDA margin, the impact of exchange rate fluctuations on our financial results, our expectations regarding continued growth, our expectations regarding the payment of any future quarterly dividends and the level and extent of any purchases under our expanded share repurchase program, and statements using the terms \"outlook,\" \"expect,\" or similar expressions, are \"forward-looking\" statements as defined in Section 21 of the Exchange Act. These statements are based upon our current expectations and various underlying assumptions. Although we believe there is a reasonable basis for these statements and assumptions, and these statements are expressed in good faith, these statements are subject to a number of additional factors and uncertainties. Our actual revenue and non-GAAP EBITDA margin in fiscal 2026 on a constant currency basis relative to fiscal 2025 could differ materially from the guidance presented herein, and our actual performance and results may differ materially from the performance and results contained in or implied by the forward-looking statements made herein, due to many important factors. These factors include, but are not limited to, the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions; the timing of engagements for our services; the effects of competitive services and pricing; the development and use of artificial intelligence; our ability to attract and retain key employee or non-employee experts; the inability to integrate and utilize existing consultants and personnel; the decline or reduction in project work or activity; global economic conditions including less stable political and economic environments; foreign currency exchange rate fluctuations; unanticipated expenses and liabilities; risks inherent in international operations; changes in tax law or accounting standards, rules, and regulations; our ability to collect on forgivable loans should any become due; and professional and other legal liability or settlements. Additional risks and uncertainties are discussed in our periodic filings with the Securities and Exchange Commission under the heading \"Risk Factors.\" The inclusion of such forward-looking information should not be regarded as our representation that the future events, plans, or expectations contemplated will be achieved. Except as may be required by law, we undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.</span></p><pre class=\"preformatted-zagxxLT_\" data-no-swipe=\"true\"><span> </span><br/><span>                                            CRA INTERNATIONAL, INC. </span><br/><span>                                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </span><br/><span>                          FOR THE FISCAL QUARTERS AND FISCAL YEAR-TO-DATE PERIODS ENDED </span><br/><span>                                  JANUARY 3, 2026 COMPARED TO DECEMBER 28, 2024 </span><br/><span>                                      (IN THOUSANDS, EXCEPT PER SHARE DATA) </span><br/><span> </span><br/><span>                               Fiscal Quarter Ended                      Fiscal Year-to-Date Period Ended </span><br/><span>                  ----------------------------------------------  ---------------------------------------------- </span><br/><span>                   January    As a % of   December    As a % of    January    As a % of   December    As a % of </span><br/><span>                   3, 2026     Revenue    28, 2024     Revenue     3, 2026     Revenue    28, 2024     Revenue </span><br/><span>                  ---------  -----------  ---------  -----------  ---------  -----------  ---------  ----------- </span><br/><span> Revenues         $196,963   100.0%       $176,435   100.0%       $751,583   100.0%       $687,414   100.0% </span><br/><span> Cost of </span><br/><span>  services </span><br/><span>  (exclusive of </span><br/><span>  depreciation </span><br/><span>  and </span><br/><span>  amortization)    138,924    70.5%        120,541    68.3%        519,288    69.1%        479,936    69.8% </span><br/><span> Selling, </span><br/><span>  general and </span><br/><span>  administrative </span><br/><span>  expenses          33,689    17.1%         31,266    17.7%        135,031    18.0%        125,050    18.2% </span><br/><span> Depreciation </span><br/><span>  and </span><br/><span>  amortization       3,712     1.9%          3,174     1.8%         14,140     1.9%         11,677     1.7% </span><br/><span>                   -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Income from </span><br/><span>  operations        20,638    10.5%         21,454    12.2%         83,124    11.1%         70,751    10.3% </span><br/><span> </span><br/><span> Interest </span><br/><span>  expense, net      (1,383)   -0.7%         (1,013)   -0.6%         (5,358)   -0.7%         (4,417)   -0.6% </span><br/><span> Foreign </span><br/><span>  currency gains </span><br/><span>  (losses), net       (667)   -0.3%          1,145     0.6%         (1,193)   -0.2%            (92)     --% </span><br/><span>                   -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Income before </span><br/><span>  provision for </span><br/><span>  income taxes      18,588     9.4%         21,586    12.2%         76,573    10.2%         66,242     9.6% </span><br/><span> Provision for </span><br/><span>  income taxes       5,403     2.7%          6,599     3.7%         21,791     2.9%         19,589     2.8% </span><br/><span>                   -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Net income       $ 13,185     6.7%       $ 14,987     8.5%       $ 54,782     7.3%       $ 46,653     6.8% </span><br/><span>                   =======   =====   ===   =======   =====   ===   =======   =====   ===   =======   ===== === </span><br/><span> </span><br/><span> Net income per </span><br/><span> share: </span><br/><span>    Basic         $   2.01                $   2.21                $   8.23                $   6.82 </span><br/><span>                   =======                 =======                 =======                 ======= </span><br/><span>    Diluted       $   1.99                $   2.18                $   8.14                $   6.74 </span><br/><span>                   =======                 =======                 =======                 ======= </span><br/><span> </span><br/><span> Weighted </span><br/><span> average number </span><br/><span> of shares </span><br/><span> outstanding: </span><br/><span>    Basic            6,547                   6,763                   6,641                   6,821 </span><br/><span>                   =======                 =======                 =======                 ======= </span><br/><span>    Diluted          6,627                   6,866                   6,714                   6,908 </span><br/><span>                   =======                 =======                 =======                 ======= </span><br/><span> </span><br/><span> </span><br/><span>                                             CRA INTERNATIONAL, INC. </span><br/><span>                                   RECONCILIATION OF NON-GAAP FINANCIAL MEASURES </span><br/><span>                           FOR THE FISCAL QUARTERS AND FISCAL YEAR-TO-DATE PERIODS ENDED </span><br/><span>                                   JANUARY 3, 2026 COMPARED TO DECEMBER 28, 2024 </span><br/><span>                                       (IN THOUSANDS, EXCEPT PER SHARE DATA) </span><br/><span> </span><br/><span>                                 Fiscal Quarter Ended                      Fiscal Year-to-Date Period Ended </span><br/><span>                    ----------------------------------------------  ---------------------------------------------- </span><br/><span>                     January    As a % of   December    As a % of    January    As a % of   December    As a % of </span><br/><span>                     3, 2026     Revenue    28, 2024     Revenue     3, 2026     Revenue    28, 2024     Revenue </span><br/><span>                    ---------  -----------  ---------  -----------  ---------  -----------  ---------  ----------- </span><br/><span> Revenues           $196,963   100.0%       $176,435   100.0%       $751,583   100.0%       $687,414   100.0% </span><br/><span>                     =======   =====   ===   =======   =====   ===   =======   =====   ===   =======   ===== === </span><br/><span> </span><br/><span> Net income         $ 13,185     6.7%       $ 14,987     8.5%       $ 54,782     7.3%       $ 46,653     6.8% </span><br/><span> Adjustments </span><br/><span> needed to </span><br/><span> reconcile GAAP </span><br/><span> net income to </span><br/><span> non-GAAP net </span><br/><span> income: </span><br/><span>    Non-cash </span><br/><span>     valuation </span><br/><span>     change in </span><br/><span>     contingent </span><br/><span>     consideration        --      --%           (190)   -0.1%             --      --%           (190)     --% </span><br/><span>    Restructuring </span><br/><span>     (1)(2)               --      --%             --      --%           (462)   -0.1%          8,176     1.2% </span><br/><span>    Foreign </span><br/><span>     currency </span><br/><span>     (gains) </span><br/><span>     losses, net         667     0.3%         (1,145)   -0.6%          1,193     0.2%             92      --% </span><br/><span>    Tax effect on </span><br/><span>     adjustments        (150)   -0.1%            340     0.2%           (183)     --%         (2,126)   -0.3% </span><br/><span>                     -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Non-GAAP net </span><br/><span>  income            $ 13,702     7.0%       $ 13,992     7.9%       $ 55,330     7.4%       $ 52,605     7.7% </span><br/><span>                     =======   =====   ===   =======   =====   ===   =======   =====   ===   =======   ===== === </span><br/><span> </span><br/><span> Non-GAAP net </span><br/><span> income per </span><br/><span> share: </span><br/><span>    Basic           $   2.09                $   2.06                $   8.31                $   7.69 </span><br/><span>                     =======                 =======                 =======                 ======= </span><br/><span>    Diluted         $   2.06                $   2.03                $   8.23                $   7.60 </span><br/><span>                     =======                 =======                 =======                 ======= </span><br/><span> </span><br/><span> Weighted average </span><br/><span> number of shares </span><br/><span> outstanding: </span><br/><span>    Basic              6,547                   6,763                   6,641                   6,821 </span><br/><span>                     =======                 =======                 =======                 ======= </span><br/><span>    Diluted            6,627                   6,866                   6,714                   6,908 </span><br/><span>                     =======                 =======                 =======                 ======= </span><br/><span> </span><br/><span> (1) Fiscal year-to-date ended January 3, 2026 includes restructuring and separation benefits totaling $4.9M, </span><br/><span> comprised of $3.8M in cash and $1.1M in non-cash charges; net of the reversal of $5.4M of non-cash charges </span><br/><span> associated with a previously recorded performance award. </span><br/><span> (2) Fiscal year-to-date ended December 28, 2024 includes cash severance of $2.5M and non-cash charges of $5.7M </span><br/><span> associated with portfolio optimization actions. </span><br/><span> </span><br/><span> </span><br/><span>                                             CRA INTERNATIONAL, INC. </span><br/><span>                                   RECONCILIATION OF NON-GAAP FINANCIAL MEASURES </span><br/><span>                           FOR THE FISCAL QUARTERS AND FISCAL YEAR-TO-DATE PERIODS ENDED </span><br/><span>                                   JANUARY 3, 2026 COMPARED TO DECEMBER 28, 2024 </span><br/><span>                                                  (IN THOUSANDS) </span><br/><span> </span><br/><span>                                 Fiscal Quarter Ended                      Fiscal Year-to-Date Period Ended </span><br/><span>                    ----------------------------------------------  ---------------------------------------------- </span><br/><span>                     January    As a % of   December    As a % of    January    As a % of   December    As a % of </span><br/><span>                     3, 2026     Revenue    28, 2024     Revenue     3, 2026     Revenue    28, 2024     Revenue </span><br/><span>                    ---------  -----------  ---------  -----------  ---------  -----------  ---------  ----------- </span><br/><span> Revenues           $196,963   100.0%       $176,435   100.0%       $751,583   100.0%       $687,414   100.0% </span><br/><span>                     =======   =====   ===   =======   =====   ===   =======   =====   ===   =======   ===== === </span><br/><span> </span><br/><span> Net income         $ 13,185     6.7%       $ 14,987     8.5%       $ 54,782     7.3%       $ 46,653     6.8% </span><br/><span> Adjustments </span><br/><span> needed to </span><br/><span> reconcile GAAP </span><br/><span> net income to </span><br/><span> non-GAAP net </span><br/><span> income: </span><br/><span>    Non-cash </span><br/><span>     valuation </span><br/><span>     change in </span><br/><span>     contingent </span><br/><span>     consideration        --      --%           (190)   -0.1%             --      --%           (190)     --% </span><br/><span>    Restructuring </span><br/><span>     (1)(2)               --      --%             --      --%           (462)   -0.1%          8,176     1.2% </span><br/><span>    Foreign </span><br/><span>     currency </span><br/><span>     (gains) </span><br/><span>     losses, net         667     0.3%         (1,145)   -0.6%          1,193     0.2%             92      --% </span><br/><span>    Tax effect on </span><br/><span>     adjustments        (150)   -0.1%            340     0.2%           (183)     --%         (2,126)   -0.3% </span><br/><span>                     -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Non-GAAP net </span><br/><span>  income            $ 13,702     7.0%       $ 13,992     7.9%       $ 55,330     7.4%       $ 52,605     7.7% </span><br/><span>                     -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Adjustments </span><br/><span> needed to </span><br/><span> reconcile </span><br/><span> non-GAAP net </span><br/><span> income to </span><br/><span> non-GAAP EBITDA: </span><br/><span>    Interest </span><br/><span>     expense, net      1,383     0.7%          1,013     0.6%          5,358     0.7%          4,417     0.6% </span><br/><span>    Provision for </span><br/><span>     income taxes      5,553     2.8%          6,259     3.5%         21,974     2.9%         21,715     3.2% </span><br/><span>    Depreciation </span><br/><span>     and </span><br/><span>     amortization      3,712     1.9%          3,174     1.8%         14,140     1.9%         11,677     1.7% </span><br/><span>                     -------   -----   ---   -------   -----   ---   -------   -----   ---   -------   ----- --- </span><br/><span> Non-GAAP EBITDA    $ 24,350    12.4%       $ 24,438    13.9%       $ 96,802    12.9%       $ 90,414    13.2% </span><br/><span>                     =======   =====   ===   =======   =====   ===   =======   =====   ===   =======   ===== === </span><br/><span> </span><br/><span> (1) Fiscal year-to-date ended January 3, 2026 includes restructuring and separation benefits totaling $4.9M, </span><br/><span> comprised of $3.8M in cash and $1.1M in non-cash charges; net of the reversal of $5.4M of non-cash charges </span><br/><span> associated with a previously recorded performance award. </span><br/><span> (2) Fiscal year-to-date ended December 28, 2024 includes cash severance of $2.5M and non-cash charges of $5.7M </span><br/><span> associated with portfolio optimization actions. </span><br/><span> </span><br/><span> </span><br/><span>                          CRA INTERNATIONAL, INC. </span><br/><span>                    CONDENSED CONSOLIDATED BALANCE SHEETS </span><br/><span>                               (IN THOUSANDS) </span><br/><span> </span><br/><span>                                       January 3, 2026    December 28, 2024 </span><br/><span>                                      -----------------  ------------------- </span><br/><span> Assets </span><br/><span> Cash and cash equivalents             $         18,210    $          26,711 </span><br/><span> Accounts receivable and unbilled </span><br/><span>  services, net                                 248,862              219,548 </span><br/><span> Other current assets                            36,057               23,104 </span><br/><span>                                          -------------  ---  -------------- </span><br/><span> Total current assets                           303,129              269,363 </span><br/><span> </span><br/><span> Property and equipment, net                     36,713               45,205 </span><br/><span> Goodwill and intangible assets, net            100,404              100,953 </span><br/><span> Right-of-use assets                             76,132               81,157 </span><br/><span> Other assets                                   112,495               74,761 </span><br/><span>                                          -------------  ---  -------------- </span><br/><span> Total assets                          $        628,873    $         571,439 </span><br/><span>                                          =============  ===  ============== </span><br/><span> </span><br/><span> Liabilities and Shareholders' </span><br/><span> Equity </span><br/><span> Accounts payable                      $         30,177    $          28,155 </span><br/><span> Accrued expenses                               223,460              181,413 </span><br/><span> Current portion of lease </span><br/><span>  liabilities                                    17,223               18,696 </span><br/><span> Revolving line of credit                        34,000                   -- </span><br/><span> Other current liabilities                       25,169               23,045 </span><br/><span>                                          -------------  ---  -------------- </span><br/><span> Total current liabilities                      330,029              251,309 </span><br/><span> Non-current portion of lease </span><br/><span>  liabilities                                    76,009               84,541 </span><br/><span> Other non-current liabilities                    9,237               23,516 </span><br/><span>                                          -------------  ---  -------------- </span><br/><span> Total liabilities                              415,275              359,366 </span><br/><span> </span><br/><span> Total shareholders' equity                     213,598              212,073 </span><br/><span>                                          -------------  ---  -------------- </span><br/><span> Total liabilities and shareholders' </span><br/><span>  equity                               $        628,873    $         571,439 </span><br/><span>                                          =============  ===  ============== </span><br/><span> </span><br/><span> </span><br/><span>                         CRA INTERNATIONAL, INC. </span><br/><span>              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span><br/><span>                              (IN THOUSANDS) </span><br/><span> </span><br/><span>                                                 Year Ended </span><br/><span>                                  ---------------------------------------- </span><br/><span>                                   January 3, 2026     December 28, 2024 </span><br/><span>                                  -----------------  --------------------- </span><br/><span> Operating activities: </span><br/><span>    Net income                     $        54,782    $          46,653 </span><br/><span>    Adjustments to reconcile net </span><br/><span>    income to net cash provided </span><br/><span>    by operating activities, net </span><br/><span>    of effect of acquired </span><br/><span>    businesses: </span><br/><span>    Non-cash items, net                     34,976               29,316 </span><br/><span>    Accounts receivable and </span><br/><span>     unbilled services                     (25,673)             (22,197) </span><br/><span>    Working capital items, net             (41,661)              (4,037) </span><br/><span>                                      ------------       -------------- </span><br/><span> Net cash provided by operating </span><br/><span>  activities                                22,424               49,735 </span><br/><span> </span><br/><span> Investing activities: </span><br/><span>    Purchases of property and </span><br/><span>     equipment                              (3,868)             (16,623) </span><br/><span>    Consideration paid for </span><br/><span>     acquisitions, net                          --               (1,500) </span><br/><span>                                      ------------       -------------- </span><br/><span> Net cash used in investing </span><br/><span>  activities                                (3,868)             (18,123) </span><br/><span> </span><br/><span> Financing activities: </span><br/><span>    Borrowings under revolving </span><br/><span>     line of credit                        132,000              102,000 </span><br/><span>    Repayments under revolving </span><br/><span>     line of credit                        (98,000)            (102,000) </span><br/><span>    Tax withholding payments </span><br/><span>     reimbursed by shares                   (2,862)              (3,209) </span><br/><span>    Cash dividends paid                    (13,831)             (12,300) </span><br/><span>    Repurchase of common stock             (47,149)             (33,348) </span><br/><span>                                      ------------       -------------- </span><br/><span> Net cash used in financing </span><br/><span>  activities                               (29,842)             (48,857) </span><br/><span> </span><br/><span> Effect of foreign exchange </span><br/><span>  rates on cash and cash </span><br/><span>  equivalents                                2,785               (1,630) </span><br/><span>                                      ------------       -------------- </span><br/><span> </span><br/><span> Net increase (decrease) in cash </span><br/><span>  and cash equivalents                      (8,501)             (18,875) </span><br/><span> Cash and cash equivalents at </span><br/><span>  beginning of period                       26,711               45,586 </span><br/><span>                                      ------------       -------------- </span><br/><span> Cash and cash equivalents at </span><br/><span>  end of period                    $        18,210    $          26,711 </span><br/><span>                                      ============       ============== </span><br/><span> </span><br/><span> Noncash investing and financing </span><br/><span> activities: </span><br/><span> Increase (decrease) in accounts </span><br/><span>  payable and accrued expenses </span><br/><span>  for property and equipment       $          (449)   $             598 </span><br/><span>                                      ============       ============== </span><br/><span> Excise tax on share repurchases   $          (415)   $            (270) </span><br/><span>                                      ============       ============== </span><br/><span> Asset retirement obligations      $            --    $             191 </span><br/><span>                                      ============       ============== </span><br/><span> Right-of-use assets obtained in </span><br/><span>  exchange for lease </span><br/><span>  obligations                      $         8,460    $          10,084 </span><br/><span>                                      ============       ============== </span><br/><span> Supplemental cash flow </span><br/><span> information: </span><br/><span> Cash paid for taxes               $        26,459    $          21,444 </span><br/><span>                                      ============       ============== </span><br/><span> Cash paid for interest            $         4,659    $           4,145 </span><br/><span>                                      ============       ============== </span><br/><span> Cash paid for amounts included </span><br/><span>  in operating lease </span><br/><span>  liabilities                      $        24,826    $          20,963 </span><br/><span>                                      ============       ============== </span><br/><span> </span></pre><p class=\"\"><span>View source version on businesswire.com: https://www.businesswire.com/news/home/20260226369462/en/</span></p><p class=\"\"><span>CONTACT:    Eric Nierenberg</span></p><p class=\"\"><span>Chief Financial Officer</span></p><p class=\"\"><span>Charles River Associates</span></p><p class=\"\"><span>617-425-3020</span></p><p class=\"\"><span>Nicholas Manganaro</span></p><p class=\"\"><span>Sharon Merrill Advisors</span></p><p class=\"\"><span>crai@investorrelations.com</span></p><p class=\"\"><span>617-542-5300</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226009222:0/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226009222_20260226009225:0",
            "title": "CRA Intl 4Q Rev $197M >CRAI",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226009222_20260226009225:0/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226009222_20260226009224:0",
            "title": "CRA Intl 4Q Net $13.2M >CRAI",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226009222_20260226009224:0/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226009222_20260226009222:0",
            "title": "CRA Intl 4Q EPS $1.99 >CRAI",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226009222_20260226009222:0/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226009222_20260226009223:0",
            "title": "CRA Intl 4Q Adj EPS $2.06 >CRAI",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226009222_20260226009223:0/",
            "pub_date": "2026-02-26 21:05:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226008870:0",
            "title": "Delcath Systems Reports Fourth Quarter and Full Year 2025 Results",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(13:00 GMT) </span></strong><span>*Delcath Systems 4Q Loss/Shr 5c &gt;DCTH</span><br/><strong class=\"root-Tkn6WL2y\"><span>(13:00 GMT) </span></strong><span>Press Release: Delcath Systems Reports Fourth Quarter and Full Year 2025 Results</span></p><p class=\"\"><span>Conference Call Today at 8:30 a.m. Eastern Time</span></p><p class=\"\"><span>QUEENSBURY, N.Y.--(BUSINESS WIRE)--February 26, 2026--</span></p><p class=\"\"><span>Delcath Systems, Inc. </span><span> (\"Delcath\" or the \"Company\"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025.</span></p><p class=\"\"><span>Fourth Quarter and Full Year 2025 Financial Results</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Total fourth quarter and full year revenue of $20.7 million and $85.2   million, respectively   </span><br/><span> -- HEPZATO KIT(TM) fourth quarter and full year revenue of $19.0 </span><br/><span> million and $78.8 million, respectively   </span><br/><span> -- CHEMOSAT(R) fourth quarter and full year revenue of $1.7 million </span><br/><span> and $6.4 million, respectively       </span></li><li class=\"listItem-bmN0_SHH\"><span>Gross margins of 85% for the fourth quarter and 86% for the full year     </span></li><li class=\"listItem-bmN0_SHH\"><span>Fourth quarter net loss of $1.9 million and full year net income of   $2.7 million   </span></li><li class=\"listItem-bmN0_SHH\"><span>Non-GAAP positive adjusted EBITDA for the fourth quarter and full year   of $2.4 million and $25.1 million, respectively   </span></li><li class=\"listItem-bmN0_SHH\"><span>Repurchased 628,572 common shares for $6.0 million through December 31,   2025 under the approved $25 million Share Buyback Program   </span></li><li class=\"listItem-bmN0_SHH\"><span>As of December 31, 2025, the Company had approximately $91.0 million of   cash and short-term investments and no debt </span></li></ul><p class=\"\"><span>Business Highlights</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Currently 28 active centers   </span></li><li class=\"listItem-bmN0_SHH\"><span>Approximately 140% growth in HEPZATO procedure volume in 2025 compared   to 2024   </span></li><li class=\"listItem-bmN0_SHH\"><span>Announced the publication of additional results from the FOCUS study,   \"Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic   Delivery System in Patients with Unresectable Metastatic Uveal Melanoma\"   in Journal of Cancer Research and Clinical Oncology   </span></li><li class=\"listItem-bmN0_SHH\"><span>Announced the publication of results from multiple studies by   independent investigators, including:   </span><br/><span> -- Results from the Phase 2 CHOPIN trial sponsored by Leiden </span><br/><span> University Medical Center evaluating CHEMOSAT with ipilimumab and   nivolumab in metastatic uveal melanoma at the 2025 European   Society of Medical Oncology Annual Congress showing a significant   improvement in one-year progression-free survival versus CHEMOSAT   alone   </span><br/><span> -- A long-term retrospective study conducted by researchers at the </span><br/><span> University Hospital Tübingen, Germany, \"Characterization of   long-term survivors with liver metastases from uveal melanoma   diagnosed between 2005 and 2021\", in International Journal of   Cancer   </span><br/><span> -- A long-term retrospective study conducted by researchers at the </span><br/><span> Asklepios Hospital Barmbek, Germany, \"Survival Outcome After   Percutaneous Hepatic Perfusion with High-Dose Melphalan for   Liver-Dominant Metastatic Uveal Melanoma: A 10-Year Single-Center   Experience\" in Cancers     </span></li></ul><p class=\"\"><span>\"2025 was a pivotal year in which we delivered robust procedure-volume growth, positive operating cashflow and successfully navigated temporary headwinds to stabilize the HEPZATO revenue base in the fourth quarter,\" said Gerard Michel, President and Chief Executive Officer of Delcath \"With 28 active treatment centers now delivering therapy and compelling CHOPIN data demonstrating clear clinical benefit when PHP is sequenced with checkpoint inhibitors, we enter 2026 with strong momentum. Through continued site activations, commercial expansion, and heightened physician awareness of the CHOPIN results, we expect accelerated adoption and utilization that will drive long-term value for patients and shareholders alike.\"</span></p><p class=\"\"><span>2026 Full Year Financial Guidance</span></p><p class=\"\"><span>The Company's financial outlook for fiscal year 2026:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Total CHEMOSAT and HEPZATO KIT revenue to be at least $100 million,   reflecting an increase in HEPZATO KIT volume of at least 20% over 2025,   and   </span></li><li class=\"listItem-bmN0_SHH\"><span>Gross margins in the range of 84% to 87%. </span></li></ul><p class=\"\"><span>Fourth Quarter and Full Year 2025 Results</span></p><p class=\"\"><span>Total revenue for the quarter ended December 31, 2025 was $20.7 million compared to $15.1 million for the same period in the prior year. Revenue in the quarter includes sales of $19.0 million of HEPZATO in the U.S. and $1.7 million of CHEMOSAT in Europe.</span></p><p class=\"\"><span>Total revenue for the year-ended December 31, 2025 was $85.2 million compared to $37.2 million for the same period in the prior year. Revenue in 2025 includes sales of $78.8 million of HEPZATO in the U.S. and $6.4 million of CHEMOSAT in Europe.</span></p><p class=\"\"><span>Research and development expenses for the quarter and year-ended December 31, 2025, were $9.4 million and $29.2 million, respectively compared to $2.9 million and $13.9 million for the same periods in the prior year. The increase is primarily due to costs associated with expanding the clinical team including share-based compensation expense related to an increase in headcount and initiation of the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC and mBC. In 2024, these costs are primarily related to medical affairs and regulatory costs associated with the approved products.</span></p><p class=\"\"><span>Selling, general and administrative expenses for the quarter and year-ended December 31, 2025, were $10.5 million and $43.5 million, respectively compared to $7.0 million and $29.6 million for the same periods in the prior year. The increase is primarily due to continued commercial expansion activities including marketing-related expenses and additional personnel on the commercial team. In addition, the increase in personnel along with higher grant date exercise prices has increased the share-based compensation expense.</span></p><p class=\"\"><span>Net loss for the quarter ended December 31, 2025 was $1.9 million and net income for the full year was $2.7 million, compared to net loss of $3.4 million and $26.4 million for the same periods in the prior year.</span></p><p class=\"\"><span>Non-GAAP positive adjusted EBITDA for the quarter and year-ended December 31, 2025 was $2.4 million and $25.1 million compared to adjusted EBITDA gain of $4.6 million and loss of $2.5 million for the same periods in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.</span></p><p class=\"\"><span>As of December 31, 2025, the Company had $91.0 million in cash and investments, and no debt.</span></p><p class=\"\"><span>Conference Call Information</span></p><p class=\"\"><span>To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.</span></p><p class=\"\"><span>Event Date: Thursday, February 26, 2026</span></p><p class=\"\"><span>Time: 8:30 AM Eastern Time</span></p><p class=\"\"><span>Participant Numbers:</span></p><p class=\"\"><span>Toll Free: 1-877-407-3982</span></p><p class=\"\"><span>International: 1-201-493-6780</span></p><p class=\"\"><span>Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&amp;tp_key=15ec7bd15c</span></p><p class=\"\"><span>A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website https://investors.delcath.com/news-events/events-and-presentations.</span></p><p class=\"\"><span>GAAP v. Non-GAAP Measures</span></p><p class=\"\"><span>Delcath's reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Delcath has provided in this release certain financial information that has not been prepared in accordance with GAAP. Delcath's management believes that the non-GAAP adjusted EBITDA described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Delcath's underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Delcath's industry. However, the non-GAAP financial measures that Delcath uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.</span></p><p class=\"\"><span>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT</span></p><p class=\"\"><span>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.</span></p><p class=\"\"><span>In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.</span></p><p class=\"\"><span>In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.</span></p><p class=\"\"><span>Safe Harbor / Forward-Looking Statements</span></p><p class=\"\"><span>The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company's statements regarding the possible synergy seen in the successful Phase 2 CHOPIN Trial being transferable to clinical practice; Company's 2026 financial outlook, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" \"would\" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the Company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company's ability to obtain reimbursement for the HEPZATO KIT; and the Company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.</span></p><pre class=\"preformatted-zagxxLT_\" data-no-swipe=\"true\"><span> </span><br/><span> </span><br/><span>                          DELCATH SYSTEMS, INC. </span><br/><span>                   Condensed Consolidated Balance Sheets </span><br/><span>                                (Unaudited) </span><br/><span>              (in thousands, except share and per share data) </span><br/><span> </span><br/><span> </span><br/><span>                                         December 31,      December 31, </span><br/><span>                                              2025              2024 </span><br/><span>                                        ---------------  ----------------- </span><br/><span>Assets </span><br/><span>Current assets </span><br/><span>   Cash and cash equivalents             $      43,454    $      32,412 </span><br/><span>   Short-term investments                       47,582           20,821 </span><br/><span>   Accounts receivable                          11,744           10,890 </span><br/><span>   Inventories                                  10,252            6,933 </span><br/><span>   Prepaid expenses and other current </span><br/><span>    assets                                       6,498            2,704 </span><br/><span>                                            ----------       ---------- </span><br/><span>      Total current assets                     119,530           73,760 </span><br/><span>   Property, plant and equipment, net            3,166            1,790 </span><br/><span>   Right-of-use assets                             936            1,039 </span><br/><span>                                            ----------       ---------- </span><br/><span>         Total assets                    $     123,632    $      76,589 </span><br/><span>                                            ==========       ========== </span><br/><span>Liabilities and Stockholders' Equity </span><br/><span>Current liabilities </span><br/><span>   Accounts payable                      $       2,658    $         961 </span><br/><span>   Accrued expenses                              8,191            5,078 </span><br/><span>   Lease liabilities, current                      101              105 </span><br/><span>                                            ----------       ---------- </span><br/><span>      Total current liabilities                 10,950            6,144 </span><br/><span>   Lease liabilities, non-current                  835              933 </span><br/><span>   Other liabilities, non-current                  628              766 </span><br/><span>                                            ----------       ---------- </span><br/><span>         Total liabilities                      12,413            7,843 </span><br/><span>                                            ----------       ---------- </span><br/><span>Commitments and contingencies </span><br/><span>Stockholders' equity </span><br/><span>   Preferred stock, $.01 par value; </span><br/><span>   10,000,000 shares authorized; </span><br/><span>   24,819 and 11,357 shares issued and </span><br/><span>   outstanding at December 31, 2023 </span><br/><span>   and 2022, respectively                           --               -- </span><br/><span>   Common stock, $.01 par value; </span><br/><span>    80,000,000 shares authorized; </span><br/><span>    22,761,554 shares and 10,046,571 </span><br/><span>    shares issued and outstanding at </span><br/><span>    December 31, 2023 and 2022, </span><br/><span>    respectively                                   347              331 </span><br/><span>   Additional paid-in capital                  639,145          599,881 </span><br/><span>   Accumulated deficit                        (528,848)        (531,548) </span><br/><span>   Accumulated other comprehensive </span><br/><span>    income                                         575               82 </span><br/><span>                                            ----------       ---------- </span><br/><span>      Total stockholders' equity               111,219           68,746 </span><br/><span>                                            ----------       ---------- </span><br/><span>         Total liabilities and </span><br/><span>          stockholders' equity           $     123,632    $      76,589 </span><br/><span>                                            ==========       ========== </span><br/><span> </span><br/><span> </span><br/><span> </span><br/><span> </span><br/><span> DELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and </span><br/><span>Comprehensive Income (Loss) (Unaudited) (in thousands, except share and per </span><br/><span>                                share data) </span><br/><span> </span><br/><span> </span><br/><span>                        Three months ended               Year ended </span><br/><span>                           December 31,                 December 31, </span><br/><span>                    --------------------------  ---------------------------- </span><br/><span>                        2025          2024          2025          2024 </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>Product revenue          20,728        15,100   $    85,231   $    37,205 </span><br/><span>Cost of goods sold       (3,010)       (2,126)      (11,797)       (6,188) </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>   Gross profit          17,718        12,974        73,434        31,017 </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>Operating </span><br/><span>expenses: </span><br/><span>   Research and </span><br/><span>    development </span><br/><span>    expenses              9,371         2,914        29,246        13,874 </span><br/><span>   Selling, </span><br/><span>    general and </span><br/><span>    administrative </span><br/><span>    expenses             10,531         7,021        43,528        29,553 </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>      Total </span><br/><span>       operating </span><br/><span>       expenses          19,902         9,935        72,774        43,427 </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>      Operating </span><br/><span>       income </span><br/><span>       (loss)            (2,184)        3,039           660       (12,410) </span><br/><span>Change in fair </span><br/><span> value of warrant </span><br/><span> liability                   --        (6,679)           --       (14,071) </span><br/><span>Interest income, </span><br/><span> net                        857           295         2,920           125 </span><br/><span>Other expense                (7)          (53)          (70)          (30) </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>      Income </span><br/><span>       (loss) </span><br/><span>       before </span><br/><span>       income </span><br/><span>       taxes             (1,334)       (3,398)        3,510       (26,386) </span><br/><span>Income tax expense          562            --           810            -- </span><br/><span>      Net income </span><br/><span>       (loss)            (1,896)       (3,398)        2,700       (26,386) </span><br/><span>Other </span><br/><span>comprehensive </span><br/><span>income (loss): </span><br/><span>Unrealized gain on </span><br/><span> investments </span><br/><span> adjustments               (198)          125           394           (22) </span><br/><span>Foreign currency </span><br/><span> translation </span><br/><span> adjustments               (102)          (54)           99           (31) </span><br/><span>                     ----------    ----------    ----------    ---------- </span><br/><span>Total </span><br/><span> comprehensive </span><br/><span> income (loss)      $    (2,196)  $    (3,327)  $     3,193   $   (26,439) </span><br/><span>                     ==========    ==========    ==========    ========== </span><br/><span>Common share data: </span><br/><span>   Basic income </span><br/><span>    (loss) per </span><br/><span>    common share    $     (0.05)  $     (0.11)  $      0.08   $     (0.93) </span><br/><span>                     ==========    ==========    ==========    ========== </span><br/><span>   Weighted </span><br/><span>    average number </span><br/><span>    of basic </span><br/><span>    shares </span><br/><span>    outstanding      36,445,905    32,014,365    35,821,157    28,511,393 </span><br/><span>                     ==========    ==========    ==========    ========== </span><br/><span>   Diluted income </span><br/><span>    (loss) per </span><br/><span>    common share    $     (0.05)  $     (0.11)  $      0.07   $     (0.93) </span><br/><span>                     ==========    ==========    ==========    ========== </span><br/><span>   Weighted </span><br/><span>    average number </span><br/><span>    of diluted </span><br/><span>    shares </span><br/><span>    outstanding      36,445,905    32,014,365    39,919,557    28,511,393 </span><br/><span>                     ==========    ==========    ==========    ========== </span><br/><span> </span><br/><span> </span><br/><span> </span><br/><span> </span><br/><span>DELCATH SYSTEMS, INC. Reconciliation of Reported Net Income </span><br/><span>    (Loss) (GAAP) to Adjusted EBITDA (NON-GAAP Measure) </span><br/><span>                        (Unaudited) </span><br/><span> </span><br/><span> </span><br/><span>                  Three months ended   Twelve months ended </span><br/><span>(in thousands)       December 31,          December 31, </span><br/><span>                  ------------------  --------------------- </span><br/><span>                    2025      2024      2025      2024 </span><br/><span>                   ------    ------    ------    ------- </span><br/><span>Net income </span><br/><span> (loss)           $(1,896)  $(3,398)  $ 2,700   $(26,386) </span><br/><span>   Stock-based </span><br/><span>    compensation </span><br/><span>    expense         4,512     1,612    24,232      9,767 </span><br/><span>   Depreciation        80        38       238        134 </span><br/><span>   Net interest </span><br/><span>    (income) </span><br/><span>    expense          (857)     (295)   (2,920)      (125) </span><br/><span>   Fair value </span><br/><span>    warrant </span><br/><span>    adjustment         --     6,679        --     14,071 </span><br/><span>   Income tax </span><br/><span>    expense           562        --       810         -- </span><br/><span>                   ------    ------    ------    ------- </span><br/><span>Adjusted EBITDA </span><br/><span> (Non-GAAP)       $ 2,401   $ 4,636   $25,060   $ (2,539) </span><br/><span>                   ======    ======    ======    ======= </span><br/><span> </span></pre><p class=\"\"><span>View source version on businesswire.com: https://www.businesswire.com/news/home/20260226305802/en/</span></p><p class=\"\"><span>CONTACT:    Investor Relations Contact:</span></p><p class=\"\"><span>ICR Healthcare</span></p><p class=\"\"><span>investorrelations@delcath.com</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226008870:0/",
            "pub_date": "2026-02-26 21:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226008870_20260226008870:0",
            "title": "Delcath Systems 4Q Loss/Shr 5c >DCTH",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226008870_20260226008870:0/",
            "pub_date": "2026-02-26 21:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "modular_finance:263eb6d271b70:0",
            "title": "DOVRE GROUP’S FINANCIAL STATEMENT RELEASE 1.1.–31.12.2025",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Dovre Group Plc | Stock Exchange Release | February 26, 2026, at 3:00 PM</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>The information presented in the report has not been audited.</span></strong></p><p class=\"\"><span>Suvic Oy, the Group’s largest subsidiary in terms of revenue, was declared bankrupt by a decision of the Oulu District Court on January 7, 2026. As a result of the bankruptcy of Suvic Oy, the Dovre Group lost control over the Suvic sub-group, which has been transferred to the administration of the bankruptcy estate. At the date of signing of the Financial Statements Release, the assets and liabilities of the Suvic sub-group are under the control of the respective bankruptcy estates.</span></p><p class=\"\"><span>The situation of Suvic had an immediate impact on the entire Dovre Group, and Dovre Group Plc filed for debt restructuring proceedings on January 19, 2026. On January 28, 2026, the Western Uusimaa District Court ordered the commencement of standard debt restructuring proceedings.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Measurement principles</span></strong></p><p class=\"\"><span>With respect to the Dovre Group, the financial statements have not been prepared on a going concern basis. The declaration of Suvic’s bankruptcy has resulted in the loss of control after the reporting date, and the going concern assumption is no longer applicable. Assets have been measured at no more than the amount of the entities’ total liabilities, taking into account the impairment effects arising from the expected loss of receivables to be realised in bankruptcy.</span></p><p class=\"\"><span>The measurement of the remaining Group assets is based on an estimate of their recoverable amounts.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Estimation of distribution</span></strong></p><p class=\"\"><span>In bankruptcy proceedings, the assets of the bankruptcy estate are first used to settle administrative expenses (estate liabilities), such as the remuneration of the bankruptcy administrator and other realisation and administration costs. Thereafter, claims, such as taxes, social security contributions and wage claims, are settled. Only after these liabilities have been satisfied may distributions be made to unsecured creditors.</span></p><p class=\"\"><span>The proceeds from the realisation of assets are expected to be fully absorbed by estate liabilities and secured claims. Accordingly, no distribution is expected to be available for unsecured creditors, including the parent company.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Recognition of impairment losses</span></strong></p><p class=\"\"><span>In the parent company, Dovre Group Plc, a full impairment loss has been recognised on intra-group receivables, as the recoverable amount has been assessed as nil due to the absence of an expected distribution. A full impairment loss has also been recognised on investments in subsidiaries within the Suvic sub-group, as no recoveries are expected to be received by the parent company from the bankruptcy proceedings.</span></p><p class=\"\"><span>In determining the carrying amounts of assets, factors inherent in bankruptcy proceedings have been taken into consideration. Realisation values in bankruptcy are systematically lower than market-based values, as sales occur under distressed conditions, the pool of potential buyers is limited, realisation is subject to time constraints, and the assets are often entity-specific without an active secondary market.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Uncertainties</span></strong></p><p class=\"\"><span>The measurements involve significant uncertainty. The final distribution will be determined upon completion of the bankruptcy proceedings and depends on several factors that will be confirmed during the process.</span></p><p class=\"\"><span>The realisable value of assets depends on prevailing market conditions, the number of potential buyers and the method of realisation selected. The assets of the bankruptcy estate may increase as a result of successful recovery actions, while the final amount of creditors’ claims will be determined in the claims verification process. Administrative and realisation costs of the estate depend on the duration and complexity of the proceedings.</span></p><p class=\"\"><span>Estimates will be revised in future periods if circumstances change materially or if new relevant information becomes available. Any changes to impairment losses will be recognised in profit or loss in the period in which the change becomes known. The final distribution, if any, will be recognised in profit or loss when it has been confirmed or when the bankruptcy proceedings have been concluded.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>CEO MARKKU TASKINEN:</span></strong></p><p class=\"\"><span>In the financial year 2025, Dovre Group’s operations were clearly loss-making.</span></p><p class=\"\"><span>During the year, Dovre Group’s strategic focus was clarified and the Group’s operations became increasingly concentrated on renewable energy construction and enabling the green transition. At the beginning of 2025, the sale of the Project Personnel and Norwegian Consulting businesses to NYAB AB was completed. Following the transaction, Dovre’s continuing operations have been almost entirely focused on renewable energy, with its core formed by the subsidiary Suvic Oy.</span></p><p class=\"\"><span>During 2025, Dovre Group announced on several occasions losses in projects of its subsidiary Suvic Oy and their financial impact. In connection with the negative profit warning published on March 12, 2025, the company reported significant cost overruns in two wind power projects initiated in Sweden during 2024 and estimated total losses of EUR 8.7 million and EUR 10 million from these projects, which were recognised in 2024 as the projects continued into spring 2025. Subsequently, in connection with the negative profit warning issued on July 8, 2025, the company announced that the previously reported losses were estimated to be approximately EUR 5 million higher than earlier estimated, totalling approximately EUR 23.7 million. In the negative profit warning published on October 9, 2025, the company estimated, based on an updated assessment, that an additional EUR 4.0 million in losses would be recognised from the Swedish wind farm projects, bringing the total estimated losses from the Swedish project portfolio to EUR 27.7 million, of which EUR 18.7 million was recognised in 2024 and EUR 9.0 million in 2025.</span></p><p class=\"\"><span>Despite the challenging situation, Dovre continued to identify significant long-term opportunities in the renewable energy value chain. The strategic focus was based on market outlook, but its implementation coincided with a period marked by exceptional operational challenges.</span></p><p class=\"\"><span>Measures to address the situation were accelerated during the spring, as the Board of Directors together with executive management launched an action programme to improve Suvic Oy’s competitiveness, operational efficiency and governance processes. During the second quarter, Markku Taskinen was appointed CEO of Suvic (commencing on August 4, 2025), and Olli-Pekka Vanhanen was appointed CFO of Suvic while also serving as CFO of the Group. In September, experienced transformation executive Timo Saarinen was appointed Interim CFO of both Dovre Group and Suvic. The company assessed at that time that, through strengthened leadership, improved transparency of financial administration processes and enhanced financial reporting of projects, it had achieved an accurate view of Suvic’s business situation during the third quarter. Corrective actions continued towards the end of the year to improve profitability, organisational structure and operating models.</span></p><p class=\"\"><span>In October, Dovre announced a Group-wide structural review aimed at focusing resources on operations in line with the strategy within renewable energy projects. The company estimated that, as a result of the programme, unprofitable or non-strategic operations would be divested or discontinued. With regard to the Consulting segment’s Proha and eSite businesses, it was stated in the release published on October 29, 2025, that these would no longer represent Dovre’s strategic core business.</span></p><p class=\"\"><span>The significant difficulties encountered in projects of Suvic Oy, Dovre’s subsidiary responsible for renewable energy construction, materially weakened the Group’s financial position. The main underlying factors behind the losses were identified as errors in project cost estimation, deficiencies in project management capabilities and shortcomings in forward-looking reporting. The challenges accumulated across several simultaneous projects and had severe effects on the company’s liquidity. As a result, Suvic Oy filed for bankruptcy on January 2, 2026, and was declared bankrupt on January 7, 2026.</span></p><p class=\"\"><span>The year 2026 began with Dovre Group Plc being unable to meet its obligations as they fall due and therefore being insolvent. This was due to the financial situation of Suvic Oy and, in this context, the parent company guarantees issued by Dovre Group Plc in respect of Suvic Oy’s and its sub-group’s projects, as announced on January 2, 2026. Dovre Group Plc filed for the commencement of debt restructuring proceedings on January 19, 2026. On January 28, 2026, the Western Uusimaa District Court ordered the commencement of standard debt restructuring proceedings. A successful restructuring process would enable Dovre Group Plc to avoid bankruptcy and would allow the Group and/or the parent company to remain a going concern.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>October–December 2025</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Net sales grew by 23.6 % to EUR 33.3 (27.0) million. The growth was driven by Renewable Energy segment.</span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Renewable Energy: net sales totalled EUR 32.8 (26.5) million – increase of 23.9 %.</span></li><li class=\"listItem-bmN0_SHH\"><span>Consulting: Net sales totalled EUR 0.5 (0.5) million – increase of 11.3%.</span></li></ul></li><li class=\"listItem-bmN0_SHH\"><span>EBITDA was EUR –37.7 (-17.9) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Operating profit was EUR –43.9 (-18.3) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Profit before tax was EUR -43.0 (-18.6) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Earnings for the shareholders of the parent company EUR –48.5 (-8.2) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Earnings per share were EUR -0.458 (0.077).</span></li><li class=\"listItem-bmN0_SHH\"><span>Net cash flow from operating activities totalled EUR -2.7 (-2.0) million.</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>January–December 2025</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Net sales declined by 7,5% to EUR 91.9 (99.3) million.</span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Renewable Energy: net sales totalled EUR 90.1 (97.4) million – decrease of 7.5 %</span></li><li class=\"listItem-bmN0_SHH\"><span>Consulting: Net sales totalled EUR 1.8 (1.9) million – increase of 8.1 %</span></li></ul></li><li class=\"listItem-bmN0_SHH\"><span>EBITDA was EUR –59.3(-21.1) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Operating profit was EUR -66.3 (-21.8) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Profit before tax was EUR –67.0 (-22.8) million including EUR -0.7 (-1.0) million of finance items.</span></li><li class=\"listItem-bmN0_SHH\"><span>Earnings for the shareholders of the parent company were EUR –58.2 (-8.3) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>Earnings per share totalled EUR -0.496(-0.078).</span></li><li class=\"listItem-bmN0_SHH\"><span>Net cash flow from operating activities was EUR -2.6 (-4.4) million.</span></li><li class=\"listItem-bmN0_SHH\"><span>The Board of Directors proposes that no dividend is paid for the financial year 2025 based on the annual general meeting on April 15th, 2026.</span></li></ul><p class=\"\"><em><span>Last year’s corresponding period is shown in parentheses.</span></em></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>OUTLOOK FOR 2026</span></strong></p><p class=\"\"><span>Dovre Group does not provide financial outlook guidance for 2026 in connection with the publication of the Financial Statements Release, as announced in a stock exchange release on February 18, 2026. The reason for this is the company’s ongoing debt restructuring proceedings.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>GROUP’S KEY FIGURES</span></strong></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>EUR million</span></strong></td><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>10–12 2025</span></strong></td><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>10–12 2024</span></strong></td><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>Change %</span></strong></td><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>1–12 2025</span></strong></td><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>1–12 2024</span></strong></td><td colspan=\"1\" rowspan=\"1\"><strong class=\"root-Tkn6WL2y\"><span>Change %</span></strong></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Net sales</span></td><td colspan=\"1\" rowspan=\"1\"><span>33,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>27,0</span></td><td colspan=\"1\" rowspan=\"1\"><span>23,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>91,9</span></td><td colspan=\"1\" rowspan=\"1\"><span>99,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-7,5</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>EBITDA</span></td><td colspan=\"1\" rowspan=\"1\"><span>-37,7</span></td><td colspan=\"1\" rowspan=\"1\"><span>-17,9</span></td><td colspan=\"1\" rowspan=\"1\"><span>-110,4</span></td><td colspan=\"1\" rowspan=\"1\"><span>-59,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-21,1</span></td><td colspan=\"1\" rowspan=\"1\"><span>-180,9</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>% of net sales</span></td><td colspan=\"1\" rowspan=\"1\"><span>-113,0</span></td><td colspan=\"1\" rowspan=\"1\"><span>-66,5</span></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"><span>-64,5</span></td><td colspan=\"1\" rowspan=\"1\"><span>-21,3</span></td><td colspan=\"1\" rowspan=\"1\"></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Operating profit (EBIT)</span></td><td colspan=\"1\" rowspan=\"1\"><span>-43,9</span></td><td colspan=\"1\" rowspan=\"1\"><span>-18,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-140,1</span></td><td colspan=\"1\" rowspan=\"1\"><span>-66,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-21,8</span></td><td colspan=\"1\" rowspan=\"1\"><span>-204,2</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>% of net sales</span></td><td colspan=\"1\" rowspan=\"1\"><span>-131,8</span></td><td colspan=\"1\" rowspan=\"1\"><span>-67,7</span></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"><span>-72,2</span></td><td colspan=\"1\" rowspan=\"1\"><span>-22,0</span></td><td colspan=\"1\" rowspan=\"1\"></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Profit before taxes</span></td><td colspan=\"1\" rowspan=\"1\"><span>-43,0</span></td><td colspan=\"1\" rowspan=\"1\"><span>-18,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>-131,4</span></td><td colspan=\"1\" rowspan=\"1\"><span>-67,0</span></td><td colspan=\"1\" rowspan=\"1\"><span>-22,8</span></td><td colspan=\"1\" rowspan=\"1\"><span>193,9</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>% of net sales</span></td><td colspan=\"1\" rowspan=\"1\"><span>-129,1</span></td><td colspan=\"1\" rowspan=\"1\"><span>-68,8</span></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"><span>-72,9</span></td><td colspan=\"1\" rowspan=\"1\"><span>-22,9</span></td><td colspan=\"1\" rowspan=\"1\"></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Earnings for the shareholders of the parent company</span></td><td colspan=\"1\" rowspan=\"1\"><span>-48,5</span></td><td colspan=\"1\" rowspan=\"1\"><span>-8,2</span></td><td colspan=\"1\" rowspan=\"1\"><span>-491,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-53,5</span></td><td colspan=\"1\" rowspan=\"1\"><span>-8,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-544,1</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>% of the net sales</span></td><td colspan=\"1\" rowspan=\"1\"><span>-145,4</span></td><td colspan=\"1\" rowspan=\"1\"><span>-30,3</span></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"><span>-58,2</span></td><td colspan=\"1\" rowspan=\"1\"><span>-8,3</span></td><td colspan=\"1\" rowspan=\"1\"></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Net cash flow from operating activities</span></td><td colspan=\"1\" rowspan=\"1\"><span>-2,7</span></td><td colspan=\"1\" rowspan=\"1\"><span>-2,0</span></td><td colspan=\"1\" rowspan=\"1\"><span>35,0</span></td><td colspan=\"1\" rowspan=\"1\"><span>-2,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>-4,4</span></td><td colspan=\"1\" rowspan=\"1\"><span>-40,9</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Net debt</span></td><td colspan=\"1\" rowspan=\"1\"><span>-6,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>8,1</span></td><td colspan=\"1\" rowspan=\"1\"><span>-181,5</span></td><td colspan=\"1\" rowspan=\"1\"><span>-6,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>8,1</span></td><td colspan=\"1\" rowspan=\"1\"><span>-181,5</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Debt-equity ratio % (Gearing)</span></td><td colspan=\"1\" rowspan=\"1\"><span>13,7</span></td><td colspan=\"1\" rowspan=\"1\"><span>48,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>-71,8</span></td><td colspan=\"1\" rowspan=\"1\"><span>13,7</span></td><td colspan=\"1\" rowspan=\"1\"><span>48,6</span></td><td colspan=\"1\" rowspan=\"1\"><span>-71,8</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Earnings per share, EUR</span></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"></td><td colspan=\"1\" rowspan=\"1\"></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Undiluted</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,458</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,077</span></td><td colspan=\"1\" rowspan=\"1\"><span>494,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,496</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,078</span></td><td colspan=\"1\" rowspan=\"1\"><span>536,1</span></td></tr><tr><td colspan=\"1\" rowspan=\"1\"><span>Diluted</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,458</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,077</span></td><td colspan=\"1\" rowspan=\"1\"><span>494,3</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,496</span></td><td colspan=\"1\" rowspan=\"1\"><span>-0,078</span></td><td colspan=\"1\" rowspan=\"1\"><span>536,1</span></td></tr></tbody></table></div><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>BOARD OF DIRECTORS’ PROPOSAL FOR DISTRIBUTION OF A DIVIDEND</span></strong></p><p class=\"\"><span>On December 31, 2025, the parent company’s Dovre Group Plc’s distributable funds were EUR</span></p><p class=\"\"><span>–650 409,03.</span></p><p class=\"\"><span>The Board of Directors proposes to the General Meeting that no dividend be distributed.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>FINANCIAL REPORTING IN 2026</span></strong></p><p class=\"\"><span>Dovre Group releases its financial reports in 2026 as follows:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Financial Statements review 2025: Thursday, 26 February 2026</span></li><li class=\"listItem-bmN0_SHH\"><span>Half-year financial report January–June 2026: Thursday, 20 August 2026</span></li></ul><p class=\"\"><span>Dovre Group’s Financial Statements 2025 and Annual Report 2025 will be published online at the latest during the week beginning March 23, 2026.</span></p><p class=\"\"><span>The company’s Annual General Meeting is planned to be held on Wednesday, April 15, 2026. Dovre Group’s Board of Directors will summon the meeting later.</span></p><p class=\"\"><span>Espoo, February 26, 2026</span></p><p class=\"\"><span>DOVRE GROUP PLC</span></p><p class=\"\"><span>BOARD OF DIRECTORS</span></p><p class=\"\"><span>For further information, please contact:</span></p><p class=\"\"><span>Dovre Group Plc</span></p><p class=\"\"><span>Markku Taskinen, CEO</span></p><p class=\"\"><span>Tel. +358 50 343 1482</span></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:markku.taskinen@dovregroup.com\" rel=\"nofollow\" target=\"_blank\">markku.taskinen@dovregroup.com</a></p><p class=\"\"><span>Timo Saarinen, CFO</span></p><p class=\"\"><span>Tel. +358 50 452 4215</span></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:timo.saarinen@dovregroup.com\" rel=\"nofollow\" target=\"_blank\">timo.saarinen@dovregroup.com</a></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Distribution</span></strong></p><p class=\"\"><span>Nasdaq Helsinki</span></p><p class=\"\"><span>Main media</span></p><p class=\"\"><span>www.dovregroup.com</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Attachments</span></strong></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://storage.mfn.se/edf209b7-213c-43dc-b27e-e11498baa332/dovre-fsr-2025-en-january-december.pdf\" rel=\"nofollow\" target=\"_blank\">Dovre FSR 2025 EN January December</a></p></span></div></div>",
            "link": "https://www.tradingview.com/news/modular_finance:263eb6d271b70:0-dovre-group-s-financial-statement-release-1-1-31-12-2025/",
            "pub_date": "2026-02-26 21:00:00",
            "source": "MFN by Modular Finance",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_ACSt1CNMa:0",
            "title": "Cytta Corp Transfers CyttaCOMMS IP into IGAN Corp Following Minimum Marketable Product Milestone",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Multiple National Sales and Marketing Partners Commence CyttaCOMMS IGAN™ Training</span></p><p class=\"\"><span>LAS VEGAS, NV / ACCESS Newswire / February 26, 2026 / Cytta Corp. (OTCQB:CYCA) today announced plans to transfer the CyttaCOMMS intellectual property into IGAN™ Corp , its wholly owned Special Purpose Vehicle (SPV). IGAN™ Corp is a technology company formed to commercialize and scale the IGAN™ SaaS platform for real-time streaming, communication, collaboration, and monitoring across connected environments. Multiple national sales and marketing partners have now commenced the CyttaCOMMS IGAN™ cloud-based training and familiarization process.</span></p><p class=\"\"><span>The announcement follows the recent completion of the fully SaaS Minimum Marketable Product (MMP) milestone for the CyttaCOMMS platform. The milestone validated core communications functionality and establishes a foundation for continued development and market deployment.</span></p><p class=\"\"><span>CyttaCOMMS is a communications and field-operations platform built on Cytta's proprietary IGAN™ engine, integrating real-time video, voice, data, and location intelligence into a unified operational environment designed for mission-critical applications.</span></p><p class=\"\"><span>\"The CyttaCOMMS MMP milestone confirms the performance and scalability of the IGAN engine,\" said Gary Campbell, Chairman of Cytta Corp. \"The transfer provides structural clarity as we continue advancing the platform and expanding commercial engagement.\"</span></p><p class=\"\"><span>This milestone aligns with Cytta Corp.'s recently published thought-leadership article and accompanying video, \"</span><span>The Real Value of Drones Isn't in the Air - It's in the Data,\" which highlights the growing importance of unified real-time data platforms in public safety, defense, and operational intelligence environments. The article and video are available at: https://www.linkedin.com/pulse/real-value-drones-isnt-air-its-data-natalia-sokolova-fr2bc/</span></p><p class=\"\"><em><span>Ongoing Development</span></em></p><p class=\"\"><span>Engineering development will continue with a focus on feature enhancements, integration expansion, and operational readiness across targeted vertical markets.</span></p><p class=\"\"><em><span>Strategic Capital Evaluation</span></em></p><p class=\"\"><span>IGAN™ Corp will evaluate direct strategic capital formation and partnership opportunities to support continued engineering, productization, integration expansion, and market readiness. Any such initiatives would be subject to market conditions, board approvals, and applicable regulatory requirements.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>About Cytta Corp</span></strong></p><p class=\"\"><span>Cytta Corp. is a technology company focused on secure, real-time communications and operational intelligence platforms across public safety, defense, drone/UAS, and enterprise markets. The Company develops and acquires technologies that integrate video, voice, data, and location intelligence to enable faster decision-making, enhanced situational awareness, and coordinated response in mission-critical environments.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Media Contact</span></strong></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Cytta Corp</span></strong></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Direct: +1 415-301-6644</span></strong></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Website:</span></strong><span> </span><strong class=\"root-Tkn6WL2y\"><span>www.cytta.com</span></strong></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Email:</span></strong><span> </span><strong class=\"root-Tkn6WL2y\"><span>info@cytta.com</span></strong></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>SOURCE:</span></strong><span> Cytta Corp.</span></p><p class=\"\"><span>View the original press release on ACCESS Newswire</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_ACSt1CNMa:0/",
            "pub_date": "2026-02-26 21:00:00",
            "source": "Acceswire",
            "kind": 1,
            "language": "en"
        }
    ]
}